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ABSTRACT 
Immunological aspects of experimental infection of cattle with bovine 
Immunodeficiency virus (BIV) and/or bovine leukemia virus (BLV) were studied. 
The specificity and kinetics of antibody responses to BIV antigens were detemnined 
by immunoblot analysis using two BIV recombinant fusion proteins expressed in E. 
coli. Sera from all eight BlV-lnfected cattle reacted to a p26-containing protein by 
four weeks post-inoculation (p.L). but this reactivity decreased dramatically in 
seven cattle by six months post-inoculation. In contrast, reactivity to a protein 
containing the amino terminus of BIV gp42 persisted in all animals throughout the 
four year study. BIV could be isolated from peripheral blood mononuclear cells 
(PBMC) of all animals during the period of declining p26-specific antibodies. 
However, there was no obvious increase In virus recovery during this period, nor 
were any p26-containing circulating immune complexes detected by 
immunoprecipitatlon. Therefore, the antibody loss did not appear to be attributable 
to an increasing p26 antigenemia. These findings also suggest that 
seroepidemiological surveys that rely on detection of antibodies to p26 may 
underestimate the true prevalence of BIV. Because there was no evidence of 
immunosuppressive disease In these cattle, it was hypothesized that a suppression 
of antigen-specific immune responses contributed to the loss of p26-speclfic 
antibodies. Humoral responses to vaccination with tetanus toxoid (TT) were 
detemnined, as were lymphocyte proliferative responses to TT, allogeneic cells, 
and concanavalln A, Cattle infected with BIV and BLV, or BLV only, were also 
Included in this study to examine possible viral Interactions, The only consistent 
BIV effect was a reduction in responses to concanavalin A. However, BLV-infected 
cattle had significantly enhanced secondary antibody responses to TT and bovine 
herpes vims-l. Although only one BLV-infected animal was persistently 
X 
lymphocytotic, circulating B cell and CD4+ T cell numbers were generally 
increased in BLV-infected cattle. There was also evidence for increased 
lymphocyte activation in BLV-infected cattle, including: 1) increased percentage of 
B cells expressing MHCII in freshly isolated PBMC; 2) increased percentage of B 
cells expressing CD25 and; 3) increased percentage of T cells expressing MHCII 
following short term culture of PBMC. These findings suggest that BLV may induce 
a generalized lymphocyte activation. 
1 
CHAPTER 1. GENERAL INTRODUCTION 
Dissertation Organization 
This dissertation Is composed of a general introduction, a literature review 
on the Immunopathogenesis of bovine Immunodeficiency virus (BIV) and bovine 
leukemia virus (BLV) Infections, three manuscripts, and a section summarizing 
experimental results and their implications. The manuscript entitled "Loss of gag-
specific antibody reactivity In cattle experimentally infected with bovine 
Immunodeficiency-like virus" was published in Viral Immunology (Volume 8, pages 
27-36, 1995, used by permission). The other two manuscripts, as well as part of 
the literature review, will be submitted for publication. The references cited in the 
literature review and the three papers appear at the ends of respective chapters. 
Research Summary 
All of the studies described In this dissertation were conducted using a 
group of cattle experimentally Infected with BIV only (n = 3), BIV and BLV (n = 5), 
BLV only (n = 5), or sham-Inoculated controls (n = 3). Initially, BIV recombinant 
proteins were expressed and used to characterize the specificity and kinetics of 
antibody responses to BIV. After finding that Gag-speclfic antibodies declined 
dramatically in most Infected cattle by six months post-inoculation, it was 
hypothesized that this may have been a reflection of early suppression of acquired 
Immune reponses. It was also of interest to determine whether there was any 
interaction between BIV and BLV in temris of effects on host immune responses. 
Thus, the research focus shifted to the study of the effect of BIV and/or BLV infection 
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on host immune responses to non-retroviral antigens. There were no dramatic BIV 
effects, but it was serendipitousiy discovered that cattle infected with BLV had 
significantly enhanced antibody responses to two recall antigens. Although both B 
cell and T cell numbers were also Increased In these cattle, it was hypothesized 
that lymphocyte functions may also have been altered by BLV infection. This 
hypothesis was verified by showing that an increased percentage of B cells 
expressed MHCII molecules in freshly isolated peripheral blood mononuclear cells 
(PBMC) from BLV infected cattle. Moreover, in cultured PBMC, it was shown that 
an Increased percentage of T cells from BLV-infected animals expressed MHCII 
molecules, and more B cells also expressed the IL-2 receptor alpha chain. Thus, 
while BIV appeared to have relatively mild effects on bovine immune responses, 
BLV affected both numbers and functions of lymphocytes in infected cattle. 
Practical and theoretical implications of these findings are discussed in the 
conclusion of this dissertation. 
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CHAPTER 2. LITERATURE REVIEW: IMMUNOPATHOGENESIS OF 
BOVINE IMMUNODEFICIENCY VIRUS AND BOVINE LEUKEMIA VIRUS 
INFECTIONS IN CATTLE 
Introduction 
General nature of retroviruses 
Retroviruses are enveloped RNA viruses that are distinguished by their use 
of an RNA-dependent DNA polymerase, reverse transcriptase, which generates a 
DNA proviral form which integrates into the host genome. Both genomic viral RNA 
and viral mRNA coding for viral proteins can then be transcribed from the provirus 
by the host RNA polymerase. Endogenous retroviruses are a part of the genome of 
many mammalian species, while exogenous retroviruses, which spread 
horizontally between individual hosts, are important pathogens of both humans 
and domestic animals. Retroviruses have also been of great use in both 
biotechnology and molecular biology. Retroviral reverse transcriptase is commonly 
used to make cDNA copies of cellular RNA, and modified retroviruses have much 
potential as agents to transfer genes in the therapy of genetic diseases. 
Retroviruses have been historically classified into three subfamilies; the 
Lentivirinae, Oncovirinae, and Spumavirinae, In 1991, retroviruses were re­
classified into seven separate genera according to the Fifth Report of the 
International Committee on Taxonomy of Viruses (Coffin, 1992). The lentiviruses 
and spumaviruses remained as separate genera, but the Oncovirinae were divided 
into five genera according to differences in morphology, genetics, and pathogenic 
mechanisms. Retroviruses have also been grouped according to the complexity of 
their life cycle (Cullen, 1992). Murine and avian leukemia viruses are considered 
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"simple" retroviruses, while the lentiviruses, spumaviruses, and the bovine 
leukemia virus (BLV)/human T cell leukemia virus (HTLV) group are considered to 
be "complex". The complex viruses are characterized by their possession of genes 
coding for two nuclear regulatory proteins, one which transactivates viral gene 
expression and another which promotes the expression of viral structural mRNA 
species, thus dividing the replication cycle into early and late phases. In contrast, 
simple retroviruses may require only gag, pol, and env genes for their replication. 
The lentiviruses comprise the human, simian, feline, and bovine 
immunodeficiency viruses (HIV, SIV, FIV, and BIV), as well as equine infectious 
anemia virus (EIAV), maedi-visna virus, and caprine arthritis encephalitis virus. 
These "slow" viral infections are usually characterized by long incubation periods 
with gradual development of disease, although some ElAV-infected horses have 
an acute course (Carpenter and Alexanderson, 1992). Another exception is 
Jembrana disease virus, which can cause an acute and often fatal disease in Bali 
cattle, and has recently been identified as a lentivirus (Chadwick et al., 1995). Most 
genera of cancer-causing retroviruses either preferentially insert into the host 
genome where they can activate host proto-oncogenes, or themselves possess 
oncogenes which code for growth factor-like proteins that promote tumor formation. 
In contrast, the HTLV/BLV viruses do not appear to have preferred sites of 
integration, and lack classical viral oncogenes. Although the mechanism(s) are 
incompletely understood, it is thought that BLV and HTLV contribute to tumor 
fomnation by producing regulatory proteins which not only increase viral 
transcription, but also activate host cell proliferation, leading to tumor formation in a 
relatively small number of hosts. 
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Retroviruses and the host immune system 
Because they generally infect cells important in host defense, the life cycle of 
exogenous retroviruses is inextricably linked to the immune responses of the host. 
Narayan and Clements (1989) categorized the diseases causesd by lentiviurses as 
either primary or secondary. Primary disease Is the major pathological 
manifestation of most lentivlral infections of domestic animals, and results from 
lentiviral replication in monocytes/macrophages, with dysregulation of cytokine 
production by these cells. Secondary disease results from opportunistic infections 
by other agents subsequent to loss of function of CD4+ T helper cells. Secondary 
disease has thus far only been demonstrated in infections of humans, non-human 
primates, and cats. 
The fact that most retroviruses cause persistent, life-long infections in their 
hosts Implies an ability to avoid elimination by host immune responses. An 
important strategy used by retroviruses to avoid elimination is suppression of host 
immunity. As reviewed by Specter et al. (1988), both humoral and cell-mediated 
host responses are affected by retroviral infections of mammals. At least eight 
different murine retroviruses have been reported to inhibit primary and/or 
secondary antibody production. Both feline leukemia virus (FeLV) and FIV are 
also known to inhibit antibody responses to newly encountered antigens, as does 
HIV. Cell-mediated responses may also be severely depressed, particulariy in HIV 
and FIV infection. In addition, functions of cells of the innate immune system, such 
as macrophages and NK cells, are often adversely affected. In fact, it has been 
suggested that the T cell dysfunction seen in human HIV infection is predominantly 
due to defective antigen presentation (Meyaard et al., 1993). In general, 
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retroviaises can suppress host immune functions by replicating in immune cells, 
with direct cytopathic effects, by activation of cells with suppressor activity, or by the 
production of suppressive products such as p15E of FeLV (Specter et al., 1988). In 
the case of HIV infection, many other mechanisms may play a role, such as the 
induction of programmed cell death, autoimmunity, or overwhelming antigenic 
diversity (Weiss, 1993). Thus, in addition to being Important pathogens of humans 
and domestic animals, the retroviruses have provided an impetus to increase our 
understanding of interactions between pathogens and the host immune system. 
Discovery of bovine retroviruses 
In the late 1960's and early 1970's, three bovine retroviruses were isolated 
during the search for a viral cause of the disease of cattle known as enzootic 
bovine leukosis. A significant breakthrough occurred with the demonstration that 
lymphocytes from some lymphosarcomatous cattle produced virus particles after 
being cultured in the presence of mitogens (Miller et al., 1969). Subsequent 
epidemiological studies and transmission experiments showed that this virus was 
associated with both tumor formation and persistent lymphocytosis, and it was 
named bovine leukemia virus. At about the same time, bovine syncytial virus 
(BSV), a spumavirus, was isolated by Malmquist et al. (1969) from both 
lymphosarcomatous and nomial cattle. It has not yet been associated with any 
significant bovine health problems (Jacobs et al., 1995). A third bovine retrovirus 
was isolated from the buffy coat leukocytes of an eight year old Holstein cow (R29) 
with persistent lymphocytosis, progressive weakness, and emaciation (Van Der 
Maaten et al., 1972). After further genetic and immunological characterization 
revealed it to be a lentivirus (Gonda et al., 1987), this virus was named bovine 
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immunodeficiency-like virus due to similarities to HIV. Most recently, the cause of 
Jembrana disease, an acute and often fatal infectious disease in Bali cattle (Bos 
javanicus) in Indonesia has been identified as a lentivirus that is closely related to 
BIV (Chadwick et al., 1995). Interestingly, the disease caused by this virus may be 
very species-specific, since inoculation of European cattle did not produce clinical 
signs (Soeharsono et al., 1990). Because the Jembrana disease virus has not 
been shown to occur in the United States, the remainder of this review will focus on 
BIV and BLV infection. 
Bovine Immunodeficiency Virus (BIV) 
BIV genetics and replication 
The genome of BIV is the most complex of the nonprimate lentiviruses (Fong 
et al., 1995). In addition to the obligate retroviral structural genes gag, pol, and 
env, BIV contains at least five open reading frames (ORFs) in a "central region" 
between and overlapping the pol and env genes (Gonda et al., 1987, Garvey et al., 
1990). Three of these were identified as tat, rev, and v^by their similarity to 
regulatory genes of other lentiviruses, while two unique ORFs of unknown function 
were designated IVand /(Fong et al., 1995). Similar to EIAV and visna virus, BIV 
apparently lacks a nefgene (Garvey et al., 1990), which is thought to function in 
HIV as a transcriptional silencer important in down-regulating viral expression, 
(Cullen, 1992). 
The proviral long terminal repeat (LTR) of BIV serves as the viral promoter 
for transcription initiation. The BIV tat gene codes for a transactivating protein. Tat, 
which has been shown to increase viral transcription from the 5' LTR 15 to 80 fold 
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(Pallansch et al., 1992). BIV Tat interacts with a post-transcriptional regulatory 
element, TAR, in the nascent viral RNA (Carpenter et al., 1993). Unlike the HIV Tat 
protein, BIV Tat apparently does not use cellular transcription factors to stabilize 
binding to RNA in vivo (Chen and Frankel, 1994). However, a relatively high level 
of BIV LTR activity was observed in the absence of BIV Tat in cells transfected with 
a BIV LTR-reporter gene construct, suggesting that cellular factors are also 
involved in regulating BIV gene expression (Pallansch et al., 1992). In support of 
this, several cis-acting regulatory elements have been identified in the BIV LTR 
which may play a role in determining the extent of gene expression in different ceil 
types (Fong et al., 1995). 
The Rev protein of lentiviruses promotes the stability and export of unspliced 
and single spliced mRNA coding for Gag and Env structural proteins, respectively 
(Cullen, 1992). The timing of Rev expression therefore plays an important part in 
the shift from early to late replication in complex retroviruses. The BIV Rev protein 
has been detected in BlV-infected cells, mainly in the nucleoli, and its expression 
was correlated with the appearance of Gag and Env proteins (Oberste et al., 1993). 
Genes coding for BIV structural proteins have also been characterized. The 
BIV gag gene codes for the Gag precursor, p53, which is processed by a viral 
protease into matrix (pi6), capsid (p26), and nucleocapsid (pi3) proteins (Battles 
et al., 1992), as well as 3 smaller fragments (Tobin et al., 1994). Several 
alternative Gag cleavage products have also been identified using monospecific 
sera raised against Gag peptides (Battles et al., 1992). The N terminus of the 
matrix protein of BIV was shown to lack the modification by fatty acids that is found 
in most lentiviruses (Tobin et al., 1994). Since this post-translational modification 
by fatty acids is thought to be important In localizing the Gag precursor of some 
retroviruses to the plasma membrane during vims assembly, BIV may use an 
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alternative mechanism. The BIV envgene codes for a 145 kDa precursor protein 
which is cleaved into the surface envelope gp110 and the transmembrane protein 
gp42 (Rasmussen et al., 1992). 
Genomic variability is a well-known feature of lentiviral infections, and BIV is 
no exception. Even though they were both derived from a single virus inoculation, 
the BIV 106 2ind BIV 127 infectious molecular clones were shown to have 
considerable nucleotide and amino acid sequence variation, particulariy in the 
surface envelope genes (Braun et al., 1988, Garvey et al., 1990). Similarly, more 
recent studies have shown that BIV isolates from Florida and Oklahoma have 
larger surface envelope genes compared to these BIV R29-derived molecular 
clones (Suarez et al., 1995). These findings lend support to the concept that a 
lentivirus such as BIV is actually a quasi-species consisting of many variant 
genomes. 
Host immune responses to BIV infection 
Both T cell mediated and antibody responses can be important components 
of the host response to viral infections. However, virtually no information is 
available about cell-mediated responses to BIV infection. Recombinant BIV Gag 
and Env proteins expressed in E. coli have been used to determine major epitopes 
recognized by antibodies in the serum of BlV-infected cattle; one in the carboxy 
temiinus of BIV p26 (Atkinson et al., 1992), and another in the amino temiinus of 
BIV gp42 (Chen et al., 1994). Antibody responses to specific BIV proteins have 
been characterized in BlV-infected cattle by Western immunoblotting using pelleted 
virus preparations from BlV-infected cell cultures (Whetstone et al., 1990, 1991). 
Antibodies to the BIV capsid protein, p26, were detected as eariy as 2 weeks 
following BIV inoculation. Reactivity to the surface envelope glycoprotein gp110 
was detectable in cattle by 4 to 6 weeks p.i. It was also reported that antibodies to 
p26 persisted for more than two years p.i. in experimentally infected cattle, 
depending on the sensitivity of the assay used (Whetstone et al., iggo). However, 
data from this study indicated that two out of the four animals tested at 19-38 
months p.i. had lost detectable antibody, as determined by Westem blotting and 
immunofluorescence (IFA). Moreover, in one BlV-infected calf, predominant 
antibody reactivity shifted from core to envelope several months post-BIV 
inoculation (Whetstone et al., 1991). In a more recent study, although sera from 
eight BlV-infected cattle contained antibodies reactive with a BIV p26-containing 
recombinant protein by four weeks post-inoculation (p.i.), seven animals lost 
detectable p26-specific antibodies by six months p.i. (Isaacson et al., 1995). 
Therefore, serological assays which rely on the detection of antibody reactivity to 
the major BIV core protein may underestimate the true prevalence of BIV infection. 
Prevalence of BIV infection 
The prevalence of bovine retroviral infections has largely been estimated by 
serologic surveys for virus-specific antibodies. An inherent assumption of these 
methods is that all infected animals produce a detectable quantity of antibodies to 
viral antigens present in the assay. As noted in the previous section, this is a 
potential problem In the diagnosis of BIV Infection. Other assays based on the 
detection of BIV proviral DNA in BlV-infected lymphocytes by PGR have been 
developed (Nadin-Davis et al., 1993, Suarez et al., 1995b), but the labor-intensive 
nature of these tests render them impractical for screening large numbers of 
samples. The results of several serological surveys for antibodies to BIV are 
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summarized in Table 1. Studies of herds containing greater than 100 cattle found 
between 4 and 50% prevalence rates of BIV antibodies, while even greater 
variation was seen in studies of smaller herds. 
Studies of BIV pathogenesis 
Natural infections 
As illustrated in Table 1, rates of natural BIV infection can vary considerably 
between different herds. Unfortunately, only a few seroepidemiological 
studieshave attempted to determine whether higher levels of BIV infection are 
associated with increased disease rates. Whetstone et al., (1990) studied four 
dairy cattle herds, two of which had persistent health problems. One of these latter 
herds had a high incidence of lymphoma and enlarged hemal lymph nodes; 69% 
of animals In this herd were BlV-positive by IFA. However, 74% were positive for 
BLV, although there was no correlation between infection with the two viruses. 
None of the 45 cattle In the other three herds had evidence of BIV antibodies. Thus 
it is difficult to draw conclusions from this study about the relationship of detectable 
BIV antibodies and the development of disease. In a larger study, McNab et al. 
(1994) detemnined that BIV seropositivity was significantly associated with lower 
milk production in dairy cows from 265 Canadian herds. These authors suggested 
that BlV-infected cattle that appeared clinically nomnal may have been predisposed 
to other subclinical conditions that affected production. In contrast, Detilleux et al. 
(1995) showed that cows with the highest predicted transmitting ability for 
kilograms of milk fat plus protein had the highest prevalence of antibodies to BIV. 
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Table 1. Prevalence of BIV seropositivlty in the United States and Canada. 
Percentages of BIV seroprevalence for each study are indicated in parenthesis; 
data based on a single herd are noted. Abbreviations; IFA, immunofluorescence 
assay; ELISA; enzyme-linked immunosorbent assay; WB, westem immunoblotting. 
BIV seropositive (%) Location Assay Reference 
11 of 97 (11.3%) Louisiana IFA Amborski et al.,1989 
6 of 138 (4.3%) Colorado IFA Amborski et al.,1989 
80 of 1997 (4.0%) Southem U.S. IFA Black et al.,1989 
54 of 78 (69%) 
(single herd) 
not reported IFA,WB Whetstone et al.,1990 
20 of 95 (21%) Colorado ELISA Cockerell et al.,1992 
51 of 928 (5.5%) Ontario WB McNab et al.,1994 
49 of 920 (5.5%) Ontario WB Jacobs et al.,1995 
221 of 442 (50%) Mississippi Gag ELISA St. Cyr Coats et al., 
1995 
31 of 37 (84%) 
(single herd) 
Louisiana ELISA Snider et al.,1996 
Most recently, Snider et al. (1996) reported a high rate of BIV infection in Holstein 
cows from a single herd with a high rate of encephalitis, lymphoid cell depletion, 
reproductive problems, and secondary infections. However, the number of BlV-free 
cattle in this study was too low to allow a valid statistical comparison of the effect of 
BIV. In addition, there was a high rate of BLV infection in these cattle, and other 
potential causes of the chronic health problems of these animals were not 
investigated. While it is possible, as these authors suggested, that BIV infection 
had a profound effect on these cattle that were exposed to various environmental 
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stresses, further epidemiological studies will be required to delineate the role of 
BIV in bovine disease. 
Experimental infections 
In order to reduce some of the inherent variability and extraneous factors 
that complicate the interpretation of studies of naturally infected cattle, the 
pathogenic effects of BIV infection have also been investigated in animals 
inoculated with BIV. Calves inoculated with infected cells or cell culture 
supematants from the original R29 cow developed enlargement and follicular 
hyperplasia of hemal lymph nodes, as well as a biphasic, transient lymphocytosis 
(Van Der Maaten et al., 1972). These studies were extended by Carpenter et al. 
(1992), who found that calves infected with BIV R29 for six weeks had transient 
fever, leukopenia, and lymphocytosis, as well as follicular hyperplasia in lymph 
nodes, hemal nodes, and spleen. These changes were similar to those observed 
in the early stages of HIV infection and after experimental infection of cats with FIV. 
However, because bovine viral diarrhea virus (BVDV) was present in the BIV 
inocula, it was unclear whether the clinical changes were due to BIV, BVDV, or 
both viruses (Carpenter et al., 1992). Two calves inoculated with BVDV-free 
Florida isolates of BIV developed a transient increase in mononuclear cell counts, 
but no fevers or enlarged lymph nodes were observed (Suarez et al., 1993). 
Lentiviral infections of humans, nonhuman primates, and cats have been 
associated with lymphomas (Cotter, 1993). Interestingly, an atypical T cell 
lymphosarcoma was reported in an 11 month old Holstein calf that had been 
experimentally infected with BIV for five months (Rovid et al., 1996). Although the 
role of BIV in tumor development was unclear, the animal had a monocytosis and 
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increased lymphocyte blastogenesis prior to tumor development, suggesting that 
BlV-induced immune stimulation might have contributed to tumorigenesis. 
Overall, despite some interesting observations, the role of BIV infection in 
diseases of cattle remains unclear. However, the asymptomatic stages of lentiviral 
infections in other species are often accompanied by altered immune functions. 
This suggests that BIV might similariy affect the immune responses of cattle in the 
absence of overt disease. 
Effects of BIV infection on the host immune system 
Effects on innate immunity 
Flaming et al. (1993) examined neutrophil functions in cattle experimentally 
infected with BIV. Although neutrophil functions in BlV-infected cattle at two months 
p.i. did not differ from those of age-matched controls, neutrophil antibody 
dependent cell mediated cytotoxicity (ADCC) was decreased in another group of 
cattle infected at four to five months p.i. In addition to decreased ADCC, neutrophil 
iodination was also decreased in a third group of cattle infected with various BIV 
preparations or infectious molecular clones for 19-27 months. Thus, BIV infection 
was shown to affect neutrophil functions, and duration of infection may have 
Influenced the nature of the effects on neutrophils. 
Monocyte functions have also been examined In cattle experimentally 
infected with BIV. Monocytes from three infected calves had decreases in 
superoxide anion release, phagocytic activity, and chemotactic responses 
compared to uninfected controls (Onuma et al., 1992). In contrast, monocyte 
functions were found to be nomnal in BlV-infected cattle through four years p.i. 
(Rovid et al., 1995). In this latter study, however, monocyte functions could be 
15 
inhibited in vitro by adding killed BIV or protein, suggesting that BIV is capable of 
inhibiting nnonocytes, but levels of virus replication In vivo may not have been high 
enough to inhibit the functions of circulating monocytes. 
Effects on acquired immunity 
In infections with other lentiviruses such as HIV and FIV, it is well established 
that host immune functions are often suppressed prior to more obvious alterations 
in circulating lymphocyte numbers or development of clinical disease (Shearer et 
al., 1986, Miedema et al., 1988, Torten et al., 1991, Bishop et al., 1992). Despite 
ongoing conjecture about the potential of BIV to cause immunosuppression In 
cattle (Brownlie et al., 1994), as well as the potential value of BIV as a model for 
other lentiviruses such as HIV, there have been few controlled studies of the effects 
of BIV infection on acquired immune responses. Stott et al. (1989) reported that 
two calves inoculated with BIV R29 had decreased numbers of circulating CD4+ 
cells at three to four months p.i. However, because these results have only been 
published in abstract fomn, it is difficult to evaluate their significance. In several 
long-temi studies of a single group of cattle experimentally infected with BIV R29, 
no consistent differences have been seen in the circulating lymphocyte 
subpopulations of BlV-infected cattle compared to age matched controls (Flaming 
et al., 1993, Flaming et al., in press, Isaacson et al., in preparation). 
Problems in experimental design have also plagued some studies of 
lymphocyte functions in BlV-infected cattle. Lymphocyte proliferative responses to 
the mitogens concanavalin A (Con A), pokeweed mitogen (PWM), and 
phytohemagglutinin (PHA) were reported to be decreased in two calves six months 
p.i. (Martin et al., 1991), but these conclusions were reached by comparison to a 
single control calf, which could have had higher proliferative responses simply by 
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chance. In contrast, lymphocyte proliferative responses to PHA were shown to be 
significantly increased in two groups of cattle infected with BIV for either 4-5 months 
or 19-27 months (Flaming et al., 1993). However, a long-term study of the first 
group of cattle showed that lymphocyte proliferative responses to mitogens were 
consistently decreased in cattle infected with BIV compared to uninfected controls, 
although these differences were not statistically significant (Flaming et al., in press). 
During the fifth year p.i., the Con A-stimulated proliferative responses of 
lymphocytes from these same BlV-infected cattle were slightly, but significantly, 
suppressed (Isaacson et al, in preparation). Thus it appears that the effect of BIV 
on lymphocyte functions may be variable over the course of Infection. 
Despite the well-known ability of lentiviral infections such as HIV to suppress 
antibody responses (MIedema et al., 1988, Pinching et al, 1991), only a single 
report has been published on the effect of experimental BIV infection on antibody 
responses to non-BIV antigens (Onuma et al, 1992). These investigators reported 
a delayed humoral response to mouse serum proteins in one out of three BlV-
infected calves compared to a single control calf. However, because of the low 
sample sizes involved, the delayed response in one calf could easily have been 
due to biological variation. In another study, there were no consistent differences 
in primary or secondary antibody responses to vaccination with tetanus toxoid (TT) 
in cattle infected with BIV for over three years compared to uninfected controls 
(Isaacson et al., in preparation). Therefore, there has been no clear evidence to 
date of suppression of acquired Immunity in controlled studies of BIV infected 
cattle. 
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Summary 
BiV ts a lentivirus of cattle that is similar to immunosuppressive lentiviruses 
In terms of structure, genetics, and replication strategy. During the first few weeks 
after being inoculated with BIV, calves show relatively mild signs of 
lymphoproliferation. Later in the course of infection, some deficits in neutrophil 
function and lymphocyte responses to mitogens can be demonstrated in vitro, but 
there has been no unequivocal evidence of clinically apparent immunosuppressive 
disease in BlV-inoculated cattle. Moreover, the few well-controlled studies that 
have been reported to date have not shown any consistent, significant effects of 
BIV inoculation on acquired immune responses of cattle. Thus, although BIV 
remains a potentially important factor in bovine disease, there is clearly a need for 
further well-controlled studies of the effects of BIV infection on acquired immune 
responses in cattle. 
Bovine Leukemia Virus (BLV) 
General virology 
Terminology 
Variations in the terms used to describe different manifestations of BLV 
infection has resulted in some confusion. The tenri bovine leukemia virus is itself 
misleading since leukemia implies an increase in circulating leukocytes due to 
invasion of primary tumor cells into the bloodstream, which is an uncommon event 
in BLV-induced neoplasms of cattle (Jacobs, 1980). A more descriptive term is 
bovine leukosis, since leukosis refers to a proliferation of the leukocyte-forming 
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tissue, and encompasses the lymphoid tumors as well as persistent lymphocytosis. 
The use of temis such as "leukotic" and "aleukemic" to describe cattle with various 
manifestations of BLV infection appears to mean different things to different 
authors, and should probably be avoided. 
Structure and classification 
Oncoviruses were originally classified into types A through D based on their 
morphology and patterns of budding from the cell membrane. Although BLV is 
most similar in size and morphology to the C-type retroviruses of other species, the 
budding form of the virus is slightly different from the classic type C virus (Weiland 
and Ueberschar, 1976). Moreover, the reverse triansop|i(B8^aBliBt i^rBqaiTtadf1^ 
other C-type viruses in which DNA synthesis proceeds equally well in the presence 
e oncogenioftelttraiilAn^, BLV is most closely related to the human T cell leukemia viruses 
(HTLV-I and -II), and the BLV/HTLV group is currently classified as a separate 
genus (Coffin, 1992). Infections with BLV or the HTLVs are characterized by a long 
latency period, relative absence of viremia, and lack of an oncogene or preferred 
proviral integration sites in their respective hosts. 
Genetics and replication 
The complete nucleotide sequence of the BLV genome has been reported 
(Sagata et al., 1985). The integrated BLV provirus contains typical retroviral LTRs, 
along with gag, pol, and env structural genes. The BLV gag gene codes for a 
precursor polypeptide which is cleaved into proteins plO, pi 2, pi 5, and the major 
core protein p24 (Bumy et al., 1980). Similariy, the BLV env gene codes for a 
glycosylated 72 kDa envelope precursor which is cleaved into two envelope 
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proteins, transmembrane gp30 and surface gp51. The po/gene encodes the 
reverse transcriptase as well as a protease and integrase (Bumy et al., 1980). 
Like other complex retroviruses, BLV has several regulatory genes. The 
BLV rex gene codes for a regulatory protein which sen/es an analogous function to 
lentiviral Rev proteins; that is, it facilitates transport of mRNAs coding for structural 
proteins to the cytoplasm (Derse et al., 1988). Like the HTLVs, but unlike other 
RNA tumor viruses, BLV contains a pX region between the en/gene and the 3' 
LTR that contains open reading frames that code for regulatory proteins (Rosen et 
al., 1985, Derse et al., 1987). One of these, the 38 kDa BLV Tax protein, was 
shown to specifically activate viral transcription by interacting with proviral LTR 
sequences: however, there was no evidence that BLV Tax binds directly to DNA 
(Derse et al., 1987). Thus, Tax may increase viral transcription through interactions 
with cellular transcription factors that recognize enhancer elements within the BLV 
LTR. 
The HTLV/BLV group of retroviruses exhibits relatively little genetic variation 
compared to the lentiviruses. Viral subtypes have been Identified at the genetic 
level, but these do not appear to result in antigenic differences (Bumy et al. 1980). 
Interestingly, comparison of the nucleotide sequence of an Australian BLV isolate 
with isolates from other countries showed more variation at the amino acid level of 
the gag gene than in the env gene, but antigenic differences were not detennined 
(Coulston et al., 1990). The genetic variation of BLV in vivo has also been studied 
following infection of animals with infectious BLV clones. Isolation of BLV proviral 
DNA from the PBMC of sheep18 months after injection with cloned BLV provirus 
showed an in vivo rate of nucleotide change in the env gene of 0.009%, 
corresponding to only one amino acid change per year (Rovnak et al., 1993). 
Similarly, 20 independent BLV clones derived from the PBMC of a sheep that 
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developed lymphosaracoma after being inoculated with cloned BLV had mutation 
rates in the envand LTR genes of only 0.043 and 0.041 percent, respectively, 
which was close to the the error rate of Taq polymerase used to amplify the genes 
(Willems et al., 1995). This lack of genetic variation is attributable, at least in part, 
to the fact that the reverse transcriptase of the HTLV/BLV group is less error-prone 
than that of other retroviruses (Mansky and Temin, 1994). In addition, members of 
the HTLV/BLV genus are thought to replicate more often as proviruses during cell 
division, rather than as viruses by reverse transcription (Cann and Chen, 1990). 
Regardless of the mechanistic explanation, these findings suggest that antigenic 
variation of BLV may not be an important strategy to escape Immune recognition. 
Clinical manifestations of BLV infection 
Lymphoid tumors 
Between 0.1 and 10 percent of BLV-infected cattle develop malignant 
lymphoma or lymphosarcoma (Bumy et al., 1988). These tumors are seen most 
frequently in cattle between 5 and 8 years of age and often occur in familial 
aggregations (Ferrer et al., 1980). They are characterized by a proliferation of 
neoplastic lymphocytes that results in the formation of solid tumor masses and/or 
diffuse infiltration of neoplastic cells into various tissues. The lymph nodes are 
almost invariably involved, with tumors often spreading to the abomasum, heart, 
uterus, or other organs (Miller, 1981). Common clinical signs include anorexia, 
weight loss, agalactia, lymphadenopathy, and posterior paresis or paralysis 
(Johnson and Kaneene, 1991). Death almost always occurs within weeks to 
months of the onset of clinical signs. However, cattle with heart involvement may 
die suddenly with no previous signs of disease. Economic losses associated with 
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BLV infection of cattle in the U.S. have been recently estimated to be 44 million 
dollars annually due to reduced foreign trade and losses due to lymphoma 
(Thurmond, 1987). 
Persistent lymphocytosis 
About 30 percent of BLV-infected cattle eventually develop persistent 
lymphocytosis (PL), which is generally defined as an abnormal elevation in 
numbers of circulating lymphocytes over a period of at least three months (Ferrer et 
al., 1979). Since increasing age is associated with decreasing lymphocyte counts 
in cattle, age is an important consideration in defining abnormal lymphocyte counts 
(Perman et al., 1970, Fen-er et al., 1979, Thurmond et al., 1990). Although PL may 
appear to be a pre-cancerous condition, most lymphocytotic cattle never develop 
tumors, and about one-third of the cattle that develop lymphosarcoma never 
progress through a PL stage. Thus PL is considered to result from a BLV-induced 
lymphoproliferatlon that is neither a subclinical form of cancer nor a prerequisite for 
tumor development. However, PL may not be a completely benign condition. Milk 
and fat production have been shown to decline in Holstein cattle with PL compared 
to uninfected animals (Wu et al.,1989. Da et al., 1993), and infected cows are 
culled from herds prematurely connpared to seronegative cattle (Brenner et al., 
1989, Pollari et al., 1993). 
The factors that influence the development of the B cell proliferation that 
characterizes PL remain poorly understood. However, genetics cleariy play an 
important role. The tendency for BLV-infected cattle to develop PL has been 
shown to be linked to genetic factors such as major histocompatibility complex 
(MHC) or BoLA type (Lewin and Bemoco, 1986, Lewin et al., 1988). Recently, 
Lewin et al. (1994) showed that resistance to PL development was associated with 
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the presence of the amino acids Giu-Arg at the putative antigen binding region of 
the BoLA-DFRBS MHC class II molecule, suggesting a potential role for cell-
mediated immune responses in confemng resistance to PL (Lewin et al., 1994). 
BLV+, non-PL 
At least 60% of BLV-infected cattle do not develop tumors or PL (Ferrer et al., 
1979), but the effect of BLV infection on this large group of cattle is still largely 
unknown. One difficulty is that most studies of the effects of BLV infection have not 
differentiated between PL and non-PL infected herdmates. Another problem is that 
many BLV-infected cattle may be culled from the herd prior to the development of 
clinically obvious health problems, thus the consequences of BLV Infection may be 
underestimated. In some early studies no significant differences were found 
between BLV-infected and uninfected cattle in production or reproductive 
perfomnance (Huber et al., 1981b). Interestingly, cows with a high genetic potential 
for milk production were more likely to be seropositive for BLV compared to 
herdmates with lower potential (Wu et al., 1989, Detilleux et al., 1995). Although 
the reason that BLV infection was associated with higher genetic potential is 
unknown, one possibility is that the increased physiological stress on higher-
producing cattle might increase susceptibility to BLV infection (Wu et al., 1989). 
Host immune responses to BLV infection 
Humoral responses 
Virtually all BLV-infected cattle produce virus-specific antibodies (Ferrer et 
al., 1977). Miller and Van der Maaten (1976) used agar gel immunodiffusion 
(AGID) and complement fixation (CF) tests to study humoral responses to BLV 
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antigens in BLV-inoculated calves. BLV-specific antibodies were detected by both 
methods in all Infected calves within two to three months p.i. Although CF titers 
remained relatively stable throughout the first year of observation, many sera had 
declining levels of reactivity in the p24 AG ID test, suggesting that the persistent 
reactions in the CF test were due to the presence of another BLV antigen, which 
was later determined to be gp51. The gp51 antigen was later incorporated into the 
AGID test which is intemationally recommended for screening cattle for BLV 
infection. 
Antibodies to gp51 are believed to be responsible for the BLV-neutralizing 
activity found in the serum of infected cattle (Van Der Maaten and Miller, 1990). 
Monoclonal antibodies have been generated against gp51 and used to identify 
eight antigenic sites (named A through H) on the gp51 molecule (Bruck et al., 
1982a). Sites F, G, and H were shown to be neutralizing epitopes involved in 
syncytia formation, and site G appeared to be a target for antibody mediated 
complement-dependent cytotoxicity (Bruck et al., 1982b). Once infection is 
established, however, the presence of antibodies to BLV gp51 or other antigens 
does not appear to hinder the development of PL or lymphoma, since animals with 
lymphosarcoma usually have higher antibody titers against BLV antigens 
(Deshayes et al., 1980, Heeney et al., 1988). 
Cell-mediated responses 
T cell-mediated responses may play a critical role in protection against BLV 
infection and/or disease. Inoculation of sheep with a vaccinia virus expressing BLV 
gp51 strongly suppressed titers of BLV following challenge (Ohishi et al., 1991). 
Antibodies to gp51 were not detected in vaccinated sheep, but strong delayed-type 
hypersensitivity responses developed against gp51 (Okada et al., 1993). 
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Therefore, both humoral and cell-mediated immune responses appear to 
contribute to host resistance against BLV infection. Gatei et al. (1993) measured 
CD4+ and CD8+ T cell responses from cattle and sheep to a complete series of 
overlapping peptides from gp51, each 20 amino acids In length. Protection of 
sheep against BLV challenge was correlated with CD4+ T cell responses to gp51 
peptide 51-70. Cytotoxic T cell responses were generated only against peptides 
121-140 and 131-150. This information should be useful in ongoing efforts to 
develop an effective BLV vaccine. 
Detection and prevalence of BLV infection 
Prior to the discovery of BLV, the presence of PL was used as an indicator of 
cattle most likely to develop bovine leukosis (Bendixen, 1965). This method was 
unsatisfactory, however, because some infected animals never become 
lymphocytotic while others develop tumors without progressing through a PL stage. 
Once the virus was identified, methods were developed to detect BLV In cultured 
peripheral blood mononuclear cells (PBMC). These included direct observation by 
electron microscopy (Miller et al., 1969), induction of syncytia on susceptible cells 
(Ferrer and Diglio, 1976), or immunological detection of BLV p24 expression 
(Jerabek et al., 1979). Though these methods tend to be quite sensitive, most 
require short-term culturing of PBMC of infected animals to induce virus 
expression. Cell culture is not required for methods that are based on the detection 
of BLV proviral DNA in infected cells. One such method is a highly sensitive 
polymerase chain reaction-based test which allows the detection of as few as 10 
copies of BLV in BLV-infected PBMC (Sherman et al., 1992). 
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Assays that have been developed to detect BLV-specific antibodies in 
bovine serum include the AGID (Miller et al., 1972), complement fixation (Miller and 
Van Der Maaten, 1974), immunofluorescence using fixed BLV-infected cell cultures 
(Ferrer et al., 1975), radioimmunoassay (RIA) (McDonald and Fen'er, 1976), and 
radioimmunoprecipitation (Deshayes et al., 1980). A comparison of four 
serological tests for the detection of BLV-specific antibodies showed that the 
greatest number of positive sera was detected by an RIA for gp51 (188), followed 
by RIA for p24 (187), virus neutralization (183), and AGID for gp51 (176) (Miller et 
al., 1981). Thus, although false-negative test results are more of a problem with the 
AGID test, there was 96.8% agreement between the tests. Most recently, an ELISA 
for detection of antibodies to BIV gp51 has been made commercially available. 
Rates of BLV infection in U.S. cattle have most commonly been estimated 
using the gp51 AGID test. Rates of BLV infection in U.S. herds are generally higher 
than those reported for BIV infection, ranging from 24% to 66% in dairy cattle, with 
lower rates found in beef herds (Johnson and Kaneene, 1991). As with BIV, 
seroprevalence rates as high as 95% have been reported for individual dairy herds 
(Huber et al., 1981 a). A study of 3000 Michigan dairy cattle over two years of age 
in 82 herds revealed prevalence rates between 24 and 36% by AGID (Kaneene et 
al., 1983). Longitudinal studies have also shown that BLV infection is more 
common in cattle over 2 years of age, which may be related to the closer physical 
contact and more intense management practices that cattle are exposed to at this 
time (Johnson and Kaneene, 1991). 
Seroepidemiological studies have also revealed a genetic influence on 
susceptibility to BLV infection. Cattle with BoLA type Eu28A had a significantly 
higher incidence of antibodies to BLV than those with type W10 (Stear et al.,1988) 
or W8.1 (Lewin et al., 1988a). Since the Eu28A allele is very common, these 
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authors speculated that cattle sharing the same MHC type might be less likely to 
destroy BLV-infected foreign cells, thus transmitting the infection more effectively. 
However, since other MHC alleles would be expected to differ in outbred cattle, the 
reason for this association remains uncertain. 
Pathogenic mechanisms in BLV infection 
BLV target cells 
There is considerable evidence that BLV replicates In B cells. When B cells 
of BLV-infected cattle were separated from PBMC by nylon wool adherence and 
cultured, 39% of the B-cell enriched preparation produced BLV antigen in vitro 
compared to 0.5% of the non-B cells (Paul et al., 1977). Kenyon and Piper (197Tb) 
showed that only PBMC or B ceils purified by various means would produce 
syncytia on bovine embryonic spleen cells. The production of BLV gp51 protein 
was detected by immunofluorescence in B cells isolated from the PBMC of four 
naturally infected lymphocytotic cattle either by T cell depletion or by flourescence 
activated cell sorting (Jensen et al,, 1990). 
Although B cells are the predominant target of BLV infection, it appears that 
non-B cells may also be infected under some conditions. Integrated proviral BLV 
DNA was detected in mitogen-stimulated CD4+ and CD8+ T cells from seven out of 
ten lymphocytotic cattle, although this could have been the result of in vitro infection 
(Stott et al, 1991). Similariy, Williams et al. (1988b) reported the presence of BLV 
proviral DNA in immunoaffinity purified T cells from BLV+, non-PL cattle. B cells 
from a lymphocytotic cow had the highest BLV load as determined by PCR, but BLV 
proviral DNA was also found in highly purified CD8+ T cells, monocytes, and 
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granulocytes (Schwartz et al., 1994). These findings suggest the BLV receptor is 
not restricted to a specific cell population. 
A cDNA coding for a polypeptide with properties of a putative BLV receptor 
has been isolated from MDBK cells and characterized (Ban et al., 1993). BLV gp51 
bound to recombinant phages expressing the cDNA, and mammalian cells 
transfected with the cDNA became susceptible to BLV infection. The protein was 
predicted to have a receptor-like structure with a gp51 binding region, a single 
transmembrane region, and a putative intracellular cytoplasmic domain. The cDNA 
hybridized with DNA from a wide variety of species, coinciding with the known 
broad host range of BLV. 
Tumorigenesis 
A large amount of research effort has been devoted to mechanisms of BLV 
tumorigenesis, and several published reviews have dealt extensively with this 
subject (Bumy et I., 1988, Schwartz and Levy, 1994). Therefore, only those 
aspects of BLV tumorigenesis with particular relevance to overall BLV 
pathogenesis will be summarized here. The BLV provirus is clonally integrated in 
tumors from individual cattle, but the provirus is integrated at different sites in 
different animals, providing evidence against the possibility that cell transformation 
results from cis-activation of host proto-oncogenes (Kettmann et al., 1980, 1985). A 
study of cells from lymphoid tumors from 17 cattle seropositive for BLV revealed 
that all were B cells containing one to four copies of BLV proviral DNA (Heeney 
and Valli, 1990). By comparison, proviral integration was shown to occur at a large 
number of chromosomal sites In 25-33% of circulating lymphocytes of 
lymphocytotic cattle (Kettmann et al., 1980) 
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Studies of cell clones derived from BLV-induced tumors have shown that all 
contain at least a portion of the BLV provirus, with the 3' region always being 
present (Kettmann et al., 1985). However, the expression of viral RNA is not 
required for the maintenance of the transformed state. Thus, it appears that while 
the 3' region of the BLV provirus is essential for the induction of neoplasia, once 
the required cellular genes are activated, the continued expression of the BLV 
proteins becomes unnecessary. Since cells expressing viral antigens are more 
likely to be destroyed by the anti-BLV immune response, there may be immune 
selection in vivo against transformed cells that continue to express viral proteins 
(Kettmann et al,, 1985). Another possible mechanism was suggested by the 
finding of a rare Tax cDNA in uncultured lymphocytes from BLV-infected cattle 
(Jensen et al., 1991). This showed that the Tax mRNA could itself be reverse 
transcribed and possibly integrated back into the host genome. If transcription of 
the integrated tax gene was controlled by a host cell promoter, leukemogenesis or 
lymphocyte proliferation could be the result. 
BLV expression in vivo 
Because it is difficult to detect BLV mRNA, proteins, or virions in freshly 
Isolated lymphocytes from BLV-infected cattle, BLV expression has long been 
thought to be restricted at the transcriptional level in vivo. (Baliga and Ferrer, 1977, 
Kettman et al., 1980). However, the persistence of a strong humoral response to 
several BLV proteins in neariy all infected cattle implies that viral antigens are 
expressed at sufficient levels in vivo to sustain a host immune response. Low 
levels of BLV-specific mRNA have recently been demonstrated in freshly isolated 
PBMC from BLV-infected cattle by highly sensitive techniques such as in situ 
hybridization (Lagarias and Radke, 1989) and polymerase chain reaction (PGR) 
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(Jensen et al., 1991). BLV RNA has also been detected In the plasma of a BLV-
infected cow by reverse transcriptase-directed PGR using probes specific for BLV 
pX or pol (Sherman et al., 1992). There appear to be different patterns of BLV 
expression in PL vs. non-PL cattle. Using RT PGR, the fax/rex message was 
detected in the PBMC of five out of five lymphocytotic cattle, compared to one out of 
seven infected cattle that were hematologically normal (Gockerell and Rovnak, 
1988). This correlates with the greater number of Infected cells In PL animals 
(30%) versus non-PL (< 5%) (Kettmann 1980), suggesting that there may be 
fundamental differences in the regulation or immunologic control of BLV 
expression in PL vs. non-PL cattle. 
In addition to the fax/rex mRNA, other small mRNAs have been shown to be 
produced from the pX region by altemative splicing (Alexandersen et al., 1993). 
One of these, the GIV mRNA, was detected in the PBMC of both naturally and 
experimentally infected cattle, and the highest level of GIV mRNA was found in the 
calf with the highest lymphocyte counts. This suggests that the GIV product may be 
involved in stimulating lymphocyte proliferation. A conserved seven amino acid 
sequence in the GIV protein had identity to the myb family of proto-oncogehes, 
suggesting a possible role in regulation of cellular or viral transcription. 
Although low levels of BLV mRNAs encoding regulatory proteins have been 
detected in freshly isolated PBMC from infected animals, the expression of mRNA 
coding for structural proteins appears extremely restricted. Therefore, it is unclear 
whether persistent antibody responses to BLV structural proteins in infected cattle 
result from continuous expression of these proteins at a very low level, or periiaps 
intermittent expression during periods of lymphocyte activation. An altemative 
hypothesis is that other host tissues besides PBMC may provide a source of BLV 
antigens in vivo. To investigate this possibility, the expression of BLV antigens was 
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examined in lymph node sections from BLV-infected cattle. Although cells 
expressing BLV antigen were present in intrafollicuiar and marginal zones, they 
were infrequent and solitary (Heeney et al., 1992). In another study, three 
persistently infected primary cell cultures derived from adherent ceils in PBMC of 
BLV-infected PL cattle were identified as endothelial cells (Rovnak et al., 1991). 
These cells had characteristics of lymph node post-capillary endothelial cells. 
Because similar cells are thought to come in intimate contact with lymphocytes that 
are migrating into the lymph nodes from the blood, this may be a site where 
lymphocytes could be infected in the absence of viremia. 
Plasma blocking factor 
The expression of BLV by cultured PBMC from BLV-infected cattle can be 
blocked at the transcriptional level by a soluble factor present in bovine plasma 
(Gupta and Ferrer 1982, Gupta et al., 1984). This plasma BLV blocking factor 
(PBB) is a non-immunoglobulin, non-interferon protein molecule with an apparent 
molecular weight of 150 kDa (Gupta et al., 1984). It is most commonly present in 
the plasma and lymphatic fluid of BLV-infected cattle, but it is also found in some 
BLV-free cattle (Gupta et al., 1989, Zandomeni et al., 1992). The blocking effect is 
reversible, since BLV production resumes after PBB is removed and lymphocytes 
are washed (Gupta and Ferrer, 1982). In addition, a platelet-derived factor capable 
of suppressing BLV PBB has been described (Tsukiyama, 1985). Other 
investigators have suggested that anti-BLV antibodies, especially those directed 
against gp51, may contribute to BLV-suppression in vitro (Taylor et al., 1993). 
Although the effect of these factors on BLV transcription has only been 
demonstrated In vitro, they very likely contribute to the repression of BLV 
transcription in vivo. 
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Studies of BLV replication in vitro 
Although BLV expression appears to be tightly regulated in vivo, PBMC 
from BLV-infected cattle produce viral mRNA, proteins, and virions within only a few 
hours after being placed in culture (Miller et al., 1969, Baliga and Ferrer, 1977, 
Driscoll et a!., 1977, Jensen et al., 1990). This differs from observations of other 
oncogenic retroviruses such as feline leukemia virus, which replicates continuously 
in lymphocytes in vivo or in vitro (Baliga and Ferrer, 1977). Thus BLV is an 
Interesting virus for the study of factors that control the expresssion of a leukemia 
virus in lymphoid cells. 
During antibody responses to T cell-dependent antigens in vivo, T cells 
stimulate B cell proliferation and differentiation by expressing costimulatory 
molecules on their surface which interact with ligands on B cells, as well as by 
secreting soluble cytokines. The influence of T cells and T cell-derived factors on 
the expression of BLV by infected B cells has been investigated. It has long been 
known that PHA, a T cell mitogen, enhances BLV expression in cultured 
lymphocytes (Muscoplatt 1974b, Baliga and Ferrer, 1977), and conditioned 
medium from cultured T cells of BLV-free sheep greatly enhanced BLV production 
by infected B cells (Djilali et al., 1987). However, only a slight reduction in BLV 
expression was observed in cultures of isolated ovine B cells compared to 
nonfractionated PBMC (Jensen et al., 1990). Therefore, while T cell-derived factors 
appear to enhance BLV expression, T cells do not appear to be required for BLV 
expression In vitro. 
Because BLV expression is augmented in vitro by factors that activate 
lymphocytes such as mitogens oranti-IgM antibodies (Lagarias and Radke, 1989), 
it has been hypothesized that activation of BLV-infected cells In vivo may stimulate 
BLV replication. This possibility was investigated in vitro using BLV-infected fetal 
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lamb kidney (FLK) cells synchronized with respect to cell cycle stage. The 
production of BLV antigens was found to be increased during the S and G2 phases 
and decreased during M and G1 (Takashlma and Olsen, 1981). Treatment of FLK 
cells with DNA synthesis inhibitors hydroxyurea and mitomycin C inhibited BLV 
antigen production, thus It was suggested that the production of BLV antigens 
requires that infected lymphocytes enter the S phase of the cell cycle. However, 
Chatterjee et al. (1985) found that the enhancing effect of PHA on BLV expression 
in vitro was not due to the mitogenic activity of PHA, since PHA stimulation of BLV 
antigen production by cultured lymphocytes occured prior to any detectable 
Increase In either DNA or RNA synthesis. The PHA effect was abolished by 
inhibition of protein synthesis with cyclohexamide, indicating that the enhancement 
of BLV expression was mediated by a PHA-induced protein. 
In general, various studies have shown that BLV expression in vitro is 
enhanced by several agents which are known to activate B cells. As noted 
previously, BLV transcription has been shown to be regulated by the Tax protein, 
which may enhance the binding of cellular proteins to the viral LTR. One host 
factor that has been shown to be Involved In BLV transcription is the cyclic AMP-
responslve element (CREB) protein. Three cyclic AMP response elements have 
been found upstream of the transcriptional start site in the BLV LTR (Willems et al., 
1992). Nuclear lysates of B cells from BLV-infected lymphocytotic cattle contained 
proteins that specifically bound to the Tax responsive element In the BLV LTR 
(Adam et al., 1994). A monoclonal antibody against the CREB protein supershifted 
a protein-DNA complex present only in BLV-infected B cells, indicating that the 
CREB protein is involved in BLV transcription in vivo. In addition, an NF-kB binding 
site has been identified upstream of the transcriptional start site in the BLV LTR 
(Brooks et al., 1995). This site was shown to bind several members of the kB family 
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of proteins, and to function as an enhancer element when inserted upstream of a 
reporter gene. Since NF-kB is constitutively expressed in B cells (Mauxion et al., 
1991), interactions between NF-kB and the BLV LTR may be responsible for a low 
basal level of BLV transcription in vivo. Upon B cell activation, an increased 
binding of NF-kB to the BLV LTR could further enhance BLV replication. 
Spontaneous lymphocyte proliferation (SLP) 
Cultured lymphocytes from BLV-infected animals with or without PL often 
display high levels of spontaneous 3H-thymidine uptake in the absence of 
mitogenic stimulation in vitro (Muscoplat et al., 1974b, Kenyon and Piper 1977a, 
Takashima and Olsen, 1980, Williams et al., 1988b, Rovnak et al., 1993, Sordillo et 
al., 1994). Although the mechanistic basis for SLP is unclear, the timing of SLP 
coincides with BLV expression in vitro (Rovnak et al., 1993). A positive correlation 
was shown between a BLV-infected animal's circulating lymphocyte count and the 
amount of ^H-thymidine incorporated by cultured PBMC during the first hour after 
blood sampling (Chandler and Gilman, 1974). Since a greater percentage of 
lymphocytes are infected in lymphocytotic cattle (Kettmann et al., 1980, Cockerell 
and Rovnak, 1988), the degree of SLP may be detemnined by the virus load of a 
particular animal. 
Two main explanations have been offered to account for SLP; 1) that it 
results from a specific immune response to BLV antigens produced in vitro, and; 2) 
that it reflects a polyclonal lymphocyte proliferation induced by BLV or BLV 
proteins. In an eariy study, Kenyon and Piper (1977b) determined that SLP 
resulted from expansion of an uninfected B cell fraction, and they suggested that 
this was a specific response to BLV antigens. This hypothesis was strengthened 
by the observation that anti-BLV serum added to lymphocyte cultures abrogated 
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the proliferative response by a non-cytolytic mechanism (Takashima and Olsen, 
1980, Thom et a!., 1981). Thus the available evidence appears to support the Idea 
that SLP in BLV-lnfected cattle results from a virus-specific immune response. In 
the HTLV system, however, it has been shown that soluble HTLV Tax protein 
added to cultured human lymphocytes rapidly translocates to the nucleus and 
induces SLP as well as increasing the expression of the interleukln-2 receptor 
alpha chain (Mariott et al. 1991, 1992). The use of fax expression plasmids would 
allow analogous experiments to be performed with bovine cells, and would 
facilitate the generation of BLV Tax-specific monoclonal antibodies for use in 
further investigations of the role of Tax in BLV pathogenesis. 
Effects of BLV infection on the host immune system 
B cell numbers 
By definition, BLV-infected cattle with PL have elevated numbers of 
circulating lymphocytes in their peripheral blood. Several methodologies have 
been used to Identify the affected lymphocyte subsets. Prior to the development of 
monoclonal antibodies (MAbs) specific for lymphocyte surface markers, T cells 
could be identified by their tendency to form rosettes when incubated with sheep 
red blood cells (sRBC), and B cells by rosette fomnation with complement-coated 
sRBC. The development of well-characterized and workshop-confirmed MAbs 
against bovine B and T cell markers has allowed a more detailed characterization 
of changes that occur in circulating lymphocyte subsets of BLV-infected cattle using 
either immunofluorescence techniques or flow cytometry. The findings of many of 
these studies are summarized in Table 2. 
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Table 2. Reported B ceil percentages and/or absolute numbers in control vs. BLV-
Infected cattle with or without PL. A single number indicates that only group means 
were reported for a particular study. Absolute numbers of cells (10^ cells/ l^) are 
listed for those studies that reported them. The number of cattle in each group is 
given in parentheses, 'Reported to be significantly different from the control group 
(P < 0.05). 
Control (n) BLV+, non-PL (n) BLV+, PL (n) Reference 
28% (12) ND 63% (4) Muscoplat et al., 1974a 
15-30% (14) 12-50% (8) 54-76% (6) Kenyon and Piper, 
1977a 
15-30% (6) ND 28-58% (8) Takashima et al., 1977 
16% (12) ND 62%* (5) Kumar et al., 1978 
11% (20) ND 59% (3) Paul et al., 1979 
29% (5) 40% (11) 85% (10) Esteban et al., 1985 
18% (12) 16-58% (2) 48-82% (4) Possum et al., 1988 
26% (4) 21% (4) 58%* (3) Williams et al., 1988a 
37% / 4002 (67) 45%/4144 (125) 78% / 15645 (16) Lewin et al., 1988b 
30%/1880 (6) 29% /1429 (6) 75% / 8785* (6) Gate! et al., 1989 
31%/1681 (15) 29% /1095 (16) 73%/9911* (11) Taylor et al., 1992 
1370 (4) 691 (4) 13633 (4) Meirom et al., 1993 
1240 (7) 2010 (7) 9820 (2)* Sordillo et al., 1994 
498 (6) ND 8666 (8)* Stone et al., 1994 
16%/560 (6) ND 57% / 8593 (8)* Stone et al., 1995 
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Virtually all these studies found that BLV-infected cattle with PL have a 
drannatic increase in the percentage and/or absolute number of circulating B cells, 
although the ranges may overlap. Reports of B cell numbers were more variable 
for BLV-infected cattle without PL. In at least two reports, B cell numbers were 
reported to be decreased in BLV+, non-PL cattle (Meirom et al, 1993, Taylor et al., 
1992). Variations in sample size, duration of infection, natural vs. experimental 
infection, failure to control for the age-related decline in total lymphocyte counts 
may all have contributed to these differences. Alternatively, these reported 
differences may reflect biological reality~i.e, that some BLV+, non-PL cattle have 
an Increase in B cell numbers, while others have a decrease. This possibility was 
alluded to by Meirom et al. (1993), who suggested that genetic differences may 
cause B cell number to decrease in some animals. One straightfonward way that 
such genetic differences might be manifested would be In an enhanced ability to 
present certain BLV antigens on MHC Class I molecules, which could render BLV-
infected cells more prone to destruction in these animals. It would therefore be of 
interest to detemriine whether BLV-infected cattle with increased B cell counts have 
relatively weak cytotoxic T cell reactivity to BLV compared to hematologically 
normal animals. 
B cell phenotypes 
In addition to being increased in number, B cells from BLV-infected cattle 
can have altered morphology and surface molecule expression. Possum et al. 
(1988) found that 3.4 to 9.7% of B cells from BLV-infected cattle with PL were 
enlarged blastoid type cells, compared to 0.3% for a single control animal. B cells 
in freshly isolated PBMC from lymphocytotic cattle also have increased levels of 
surface Ig (Possum et al., 1988, Matheise et al., 1992) and MHC class II molecules 
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(Fossum et al., 1988, Stone et al., 1995). In addition, a significant increase in the 
percentage of B cells expressing MHCII was found in freshly isolated PBMC of 
BLV+, non-PL cattle compared to uninfected controls (Isaacson et al., in 
preparation). Increased expression of MHCII molecules is an early manifestation of 
the B cell activation process, and cross-linking of class II molecules on resting 
human B cells is associated with phosphatidyl inositol turnover, protein tyrosine 
phosphorylation, and proliferation (Lane et al., 1990). Increased numbers of 
mitogen-stimulated B cells from BLV-infected cattle with PL were also found to 
express the inducible alpha chain of the IL-2 receptor (CD25), suggesting that BLV 
infection rendered B cells more sensitive to activation by T cells (Stone et al., 
1994). A similar increase in B cell CD25 expression was also observed in cultured 
PBMC from BLV+, non-PL cattle, suggesting that an enhanced expression of 
molecules important in T cell-B cell interactions may not be sufficient for the 
development of PL (Isaacson et al., in preparation). 
The development of PL in BLV-infected cattle and sheep is also 
characterized by a dramatic expansion of the CD5+ B cell population (Letesson et 
al., 1990a, 1990b, Matheise et al., 1992). The CDS marker is nomnally expressed 
on all mature T cells and on a small proportion of B cells (Ly1+ B cells in mice) 
(Hayakawa and Hardy, 1988). A minor subpopulation of CD5+ B cells is normally 
found in newborn mice or human fetus and is believed to derive from a distinct cell 
lineage. Increased numbers of CD5+ B cells are present in human B cell chronic 
lymphocytic leukemia and autoimmune diseases such as Sjogren's syndrome, 
systemic lupus erythematosus and rheumatoid arthritis, as well as in some HIV-
infected individuals (Raveche, 1990). 
The function of CDS on B cells is unclear, but there is evidence that it is a 
marker of B cell activation, since CDS can be induced on CDS-negative B cells by 
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phorbol ester or other stimulatory conditions (Wemer-Fabre 1989). A monoclonal 
antibody directed against bovine CDS enhanced mitogen-induced blastogenesis 
and IL-2 production in vitro, but did not directly stimulate cell division (Letesson et 
al, 1990a). Interestingly, an increased percentage (>15%) of CD5+ B cells in 
lymphocytotic cattle were shown to be activated cells with respect to Increased 
DNA content and responsiveness to an IL-2-containing supernatant (Maltheise et 
al., 1992). However, It is currently unknown whether BLV preferentially infects 
CD5+ B cells, resulting in their proliferation in some animals, or whether BLV-
infected B cells express CDS after becoming infected. A third possibility is that 
CD5+ B cells are involved in Immune responses against BLV antigens, as has 
been suggested in other retroviral infections (Raveche, 1990). Since CDS- B cells 
were also increased in lymphocytotic cattle (Meirom et al., 1993), and BLV provirus 
has been detected by PCR in both CD5+ and CDS- B cells (Schwartz et al., 1994a), 
a restricted BLV tropism for CDS+ B cells is an unlikely explanation for the BLV-
induced CD5+ B cell expansion. The ligand for CDS on T cells Is the CD72 protein 
found exclusively on B cells (Van de Velde et al., 1991), raising the intriguing 
possibility that enhanced CDS expression may tend to increase the activation state 
of BLV-infected B cells via autostimulatory interactions between CDS and CD72 on 
the same cell (Maltheise et al., 1992). 
T cell numbers 
Compared to B cell numbers, there are more discrepancies in these reports 
of T cell numbers in BLV-infected cattle. One area of agreement is that the 
percentage of circulating T cells Is decreased in BLV-infected cattle with PL. 
However, since B cell numbers are often dramatically increased in these animals, T 
cell percentages would be expected to decrease, even though absolute T cell 
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numbers may be increased. As shown in Table 3, absolute T cell numbers have 
been reported to be decreased (Gatei et al.,1989), unchanged (Taylor et al., 1992), 
or Increased (Stone et a!., 1994,1995) in BLV-infected cattle with PL. As 
mentioned for B cell data, these variations may be due to biological variation, or 
may reveal flaws in experimental design. For example, in one study where 
absolute T cell numbers were reported to be decreased in lymphocytotic cattle 
(Gatei et al., 1989), the controls were much younger animals that would have been 
expected to have higher lymphocyte numbers because of the age-related decrease 
in lymphocyte counts that normally occurs in cattle. Ratios of GD4/CD8 T cells 
appear to be normal in BLV-infected non-PL cattle (Stone et al., 1994, 1995), but B 
cell/T cell ratios increased from less than 1:1 to as high as 5:1 in animals with PL 
Table 3. Reported T cell percentages and/or absolute numbers in control vs. BLV-
infected cattle with or without PL. See Table 2 for legend. 
Control(n) BLV+, non-PL(n) BLV+, PL(n) Reference 
13-26% (6) ND 4-27% (8) Takashima et al., 1977 
31% (5) 29% (11) 14% (10) Esteban et al., 1985 
63% (20) ND 35% (3) Paul et al., 1979 
60-68% (12) ND 3x decrease (4) Possum et al., 1988 
56%(4) 66%' (4) 34%* (3) Williams et al., 1988 
3014 (6) 2196 (6) 1921 (6) Gatei et al., 1989 
51%/2685 (15) 56% 72081* (16) 19%/2931 (11) Taylor et al., 1992 
2250 (7) 1640 (7)* 1100 (2)* Sordillo et al., 1994 
2170 (6) ND 4565 (8)* Stone et al., 1994 
1835 (6) ND 2800 (8)* Stone et al., 1995 
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(Kumar et al., 1978, Gatei et al., 1989, Stone et al., 1994). The effect of such an 
alteration in normal lymphocyte proportions on T cell-B cell Interactions In vivo is 
unknown. 
Effects on innate immunity 
There have been relatively few studies of the effect of BLV infection on cells 
of the Innate immune system. The natural cytotoxic activity of PBMC against BLV-
infected FLK cells was significantly reduced in BLV-infected cattle with tumors or 
PL compared to non-PL or uninfected cattle (Yamamoto et al., 1984). Most sera 
from cattle in the terminal stages of BLV lymphoma inhibited the phagocytic activity 
of nomial bovine neutrophils (Takamatsu et al., 1988), but clinically healthy cows 
seropositive for BLV had increased in vitro neutrophil migration and production of 
superoxide anion, suggesting neutrophil activation (Kehrii et al., 1991). Similar 
findings were reported In a group of BLV-inoculated cattle, which had a transient 
increase in random neutrophil migration during the first year p.i. (Flaming et al., in 
press). BLV infection has also been shown to alter cytokine responses of bovine 
peripheral blood monocytes to LPS stimulation in vitro. Increased amounts of IL-1 
beta and TNF were detected in supematants of LPS-treated monocytes isolated 
from BLV-infected cattle compared to those of uninfected animals (Weriing et al., 
1995), corresponding with a previous report that monocytes may be a reservoir for 
BLV infection (Heeney et al., 1992). Both IL-1 and TNF can stimulate T and B cell 
proliferation (Ranges et al., 1988), which might contribute to the BLV-induced 
increase in these cell populations seen in some animals. Most recently, freshly 
isolated monocytes/macrophages from BLV-infected cattle with tumors or PL were 
shown to contain increased interieukin 10 mRNA compared to non-PL or 
uninfected animals (Pyeon et al., 1996). IL-10 is known to decrease the production 
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of cytokines such as IL-2 and gamma interferon gamma by T helper 1 (TH1) cells in 
mice, and levels of mRNA coding for these two cytokines were decreased in PBMC 
from BLV-lnfected cattle with PL These observations support a role for 
monocytes/macrophages in the progression of BLV-induced disease, and suggest 
that TH1-type responses may be inhibited In BLV infected cattle with PL or tumors. 
Effects on acquired immunity 
Many studies of the alterations in lymphocyte subpopulations that occur in 
BLV-lnfected cattle have been purely descriptive, without consideration of the 
functional implications of phenotypic changes. However, the central role played by 
B cells in BLV infection implies that B cell functions may be affected. The most 
obvious abnormalities in B cell function are seen in cattle suffering from the 
temninal stages of BLV-induced lymphoid tumors. Serum IgM was found to be 
decreased or absent in 80% of cows with lymphoma (Trainin et al., 1976), and no 
IgM-producing cells were found in the tumorous lymph nodes of BLV-infected cattle 
(Trainin et al., 1971). Cows with lymphoma also had impaired primary IgM 
responses to a synthetic peptide antigen and to human serum albumin (Trainin 
1976). There was also some evidence that antibodies of the IgM class had an 
abnomial structure based on altered electrophoretic mobility in cattle with 
lymphoma (Ungar-Waron et al., 1978). 
Cell-mediated immune functions are also clearly suppressed in cattle with 
BLV-induced tumors. Eight of thirteen BLV-infected cattle In the terminal stages of 
lymphoma responded pooriy to intradermal injection of mitogen or extracts from 
tumors or nonnal lymphoid cells (Jacobs et al., 1981). The mechanlsm(s) behind 
this apparent immunosuppression remain unclear; however, suppression due to 
soluble serum factors is commonly seen in the serum of animals and humans with 
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advanced cancer. A soluble inhibitor of nomnai lymphocyte blastogenesis has 
been detected in sera from BLV-infected cattle with lymphoma (Jacobs et al., 
1981); however, sera from most cattle with non-BLV sporadic lymphoma also 
suppressed blastogenesis, suggesting that the factor was not BLV-specific 
(Takamatsu et al., 1988). Therefore, although immunosuppression is commonly 
seen in EBL, it is not necessarily an Integral feature of BLV Infection per se. 
Although there is no doubt that cattle in the terminal stages of BLV-induced 
lymphoma are immunosuppressed, the data are much less clear in BLV-infected 
cattle that remain clinically healthy. Similar to BLV-infected cattle with tumors, 
those with PL also have lower levels of semm IgM, but serum IgG levels have been 
reported to be unaffected (Meirom et al., 1985, Heeney et al., 1988, Gatei et al., 
1990) or increased (Atluru et al., 1979). These findings have been interpreted as 
evidence that BLV preferentially inhibits IgM-producing cells. Another possibility 
that should be considered, however, is that BLV infection may stimulate B cell 
differentiation and antibody class switching, resulting in decreased numbers of B 
cells expressing IgM. It has recently been shown that secondary antibody 
responses to recall antigens were significantly increased in a group of BLV-
infected cattle compared to uninfected controls (Isaacson et al., In preparation). 
This adds support to the idea that instead of causing immunosuppression, BLV 
may cause a generalized B cell activation under some conditions. 
The limited data on cell-mediated responses of clinically healthy, BLV-
infected cattle appear to be in conflict. There have been several reports that 
lymphocytes from BLV-infected cattle with PL have reduced blastogenic responses 
to mitogens, as measured by stimulation indices (Weiland and Straub, 1976, 
Takashima et al., 1980, Villouta et al.,1988). These results appear to have been 
due to the high background levels of proliferation in BLV-infected cattle (see SLP), 
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since lymphocyte proliferative responses to Con A, PHA, and PWM of BLV+, non-
PL animals was comparable to that of non-infected animals when DCPM were 
compared (Williams et al., 1988b). A highly significant correlation was reported 
between BLV infection and lack of recovery from Trichophyton verrucosum, a 
chronic fungal infection (Brenner et al., 1989), implying that cell-mediated immune 
functions may have been compromised. However, an early study found a 
significant enhancement of delayed type hypersensitivity responses in BLV-
infected cattle following immunization with Mycobacterium microti (Ressang et al., 
1980). More recently, an increased percentage of T cells have been found to 
express MHCII molecules in cultured PBMC from BLV-infected cattle, whether they 
have PL (Stone et al., 1995) or not (Isaacson et al., in preparation). All though the 
function of MHCII on T cells is unknown, it is though to be indicative of T cell 
activation (Odum et al., 1993). Sordillo et al. (1994) reported that supematants of 
cultured PBMC from BLV+, PL cattle contained significantly increased amounts of 
IL-2 compared to those of BLV+, non-PL or uninfected cattle. The results of Pyeon 
et al. diverged somewhat from this, showing that greatly increased levels of IL-2R 
and IFNg mRNA were present in uncultured PBMC of BLV+, non-PL animals 
compared to BLV+, PL cattle or uninfected controls. Since the latter study did not 
measure IL-2 production, it is unclear whether the different results obtained for 
BLV+, non-PL cattle were due to differences in the rate of translation of the IL-2 
mRNA, or perhaps to biological variation. However, these studies provide further 
evidence that BLV infection can induce abnormalities in the acquired immune 
system of cattle in the absence of tumors. 
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Summary 
BLV is a member of a group of retroviruses that occasionally cause tumors, 
but do not contain a typical retroviral oncogene or integrate at preferred sites in the 
host genome. Thus these viruses may have unique mechanisms of tumorigenesis. 
With other oncoviruses infections such as feline leukemia virus, the host immune 
system is often adversely affected, even in the absence of neoplastic disease. In 
contrast, while there is clear evidence of immunosuppression in BLV-infected cattle 
with tumors, it has been more difficult to demonstrate immunosuppression in 
clinically healthy, BLV-infected cattle. Instead, cin accumulating body of data 
suggests that BLV-infected cattle without tumors may have a generalized immune 
activation, but the implications of these findings on bovine health are unknown. 
Because of the continuing economic importance of BLV infection to the U.S. cattle 
industry, as well as the value of BLV infection as a model of HTLV infection in 
humans, it will be important to continue investigations of the effect of BLV on host 
immune functions. 
Conclusions 
Both BIV and BLV infect cells of the circulating mononuclear cell population 
In cattle. Based on comparisons to other retroviruses, it would be expected that 
both might have immunosuppressive effects on the host immune system. In cattle 
infected with BIV for several months to several years, some depression of 
neutrophil and lymphocyte function has been observed. However, very little is 
known about the effects of BIV infection on acquired Immune responses. In the 
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case of BLV, only cattle in the terminal stages of cancer are obviously 
immunosuppressed, whereas the evidence for depressed immune function in 
clinically healthy, BLV-infected cattle is being outweighed by studies showing a 
potential enhancement of various immune functions. Thus, the literature on these 
two viruses to date shows that BIV has a relatively mild suppressive effect on some 
host Immune functions, while BLV appears to enhance many immune functions in 
the majority of infected animals. 
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CHAPTER 3. LOSS OF GAG-SPECIFIC ANTIBODY REACTIVITY IN 
CATTLE EXPERIMENTALLY INFECTED WITH BOVINE 
IMMUNODEFICIENCY-LIKE VIRUS 
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Jeffrey A. Isaacson, James A. Roth, Charles Wood, and 
Susan Carpenter 
Abstract 
The development and persistence of virus-specific antibodies were 
investigated In eight cattle experimentally Infected with the R29 isolate of bovine 
immunodeflcienoy-like vims (BIV). By four weeks post-inoculation (p.i.), antibodies 
reactive to BIV gag- and env-encoded recombinant fusion proteins were detectable 
by immunoblotting in all animals. By 40 weeks p.i., seven of eight cattle had 
dramatically decreased Gag-specific antibodies, and anti-Gag reactivity remained 
very low or undetectable through 190 weeks p.i. Immunoprecipitation experiments 
revealed a similar loss of reactivity to non-denatured BIV Gag in these animals. In 
contrast, antibodies to a recombinant BIV Env protein were readily detectable 
throughout the study in all eight cattle. During the period of declining Gag 
antibody, infectious virus was recoverable from peripheral blood mononuclear cells 
of each animal. However, there was no evidence for sufficient amounts of BIV p26-
containing Immune complexes to explain the loss of anti-Gag reactivity. 
Interestingly, the single animal which maintained detectable anti-Gag reactivity 
throughout the study was repeatedly negative for virus recovery beyond 17 weeks 
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p.i. All animals have remained clinically normal for over four years p.i., with no 
evidence of consistent changes in mononuclear cell subsets. These findings 
provide evidence that in BIV infection an early decline in Gag-specific antibody 
reactivity can occur without evidence of increasing viral replication or progression 
to overt clinical disease. 
Introduction 
Lentiviral infections are typically characterized by a long incubation period 
followed by a slow, progressive disease course in the naturally infected host. 
However, there are wide variations in the clinical manifestations induced by 
lentiviruses of different species. Bovine immunodeficiency-like virus (BIV), a 
lentivirus of cattle, was originally isolated from a dairy cow with persistent 
lymphocytosis, lymphoid hyperplasia, and perivascular cuffing in the brain (34). 
Experimental infection of calves with BIV is associated with a transient increase in 
lymphocytes (9,32,34) and a lymphoid hyperplasia similar to that found early after 
infection with immunosuppressive lentiviruses (9,34). Alterations in bovine 
lymphocyte, monocyte, and neutrophil functions have been reported (14,22,25); 
however, there has been no indication of BlV-induced immmunosuppressive 
disease in cattle experimentally infected with either the original R29 isolate of BIV 
(9,34) or with recently described field isolates (32). Characterization of virus and 
host factors which contribute to this clinical quiescence in BlV-infected cattle may 
further our understanding of lentiviral pathogenesis in other species. 
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Considerable attention has been given to the association between the 
humoral response to specific human immunodeficiency virus (HIV-1) proteins and 
development of the acquired immune deficiency syndrome (AIDS). Early after HIV 
infection, predominant antibody reactivity is directed against the gag gene-
encoded p24 capsid protein (16). Overtime, seroreactivity to core proteins often 
declines in association with disease progression, while anti-envelope antibodies 
usually persist throughout the course of Infection (1,3,5,7,10,17,18,21,27,29). 
Although pattems of antibody reactivity to specific viral antigens are not as well 
characterized in lentiviral infections of domestic animals, there is some evidence 
for a similar link between a loss of antibodies to viral core antigens and disease 
development in feline immunodeficiency virus (FIV) (12,15) and visna virus (19) 
infections. 
Previous studies reported that antibodies to p26, the major BIV capsid 
protein (4), persist for more than two years p.i. in experimentally infected cattle 
(36,37). However, data indicated that two out of the four animals tested at 19-38 
months p.i. had lost detectable antibody, as determined by Westem blotting and 
IFA (36). The recent development of BIV recombinant proteins (2,11) has provided 
an abundant source of antigens, which now allows a more extensive detennination 
of the virus-specific antibody response over the course of BIV infection. These 
reagents are used in the present study to examine pattems of BIV Gag and Env-
specific antibody reactivity in cattle that have been infected with BIV for over four 
years. This information was compared with virus recovery data and clinical 
findings in order to better define the role of virus-specific antibodies in controlling 
virus replication and potential disease development. Though initially strong. Gag-
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specific antibody reactivity declined dranfiaticaliy in most cattle in the first year 
following BIV inoculation. Env-specific antibodies, however, were easily detectable 
in all animals throughout the study. In contrast to other lentiviral infections, the 
decline in reactivity to BIV Gag proteins was not associated with evidence of 
increasing viral replication, nor with any overt disease. This suggests that an 
increase in viral activity is an unlikely explanation for the loss of Gag-specific 
antibodies in BIV infection. 
Materials and Methods 
Animal inoculation, serum collection, and clinical monitoring 
Colostrum-deprived male Holstein calves, two to four months of age, were 
purchased from a local dairy and were serologically determined to be free of 
antibody to BIV, bovine leukemia virus (BLV), and bovine diarrhea virus (BVDV). 
Calves were vaccinated with killed BVDV vaccine (EXCEL 4; Bio-Ceutic, St. 
Joseph, MO) as previously described (9) and eight calves were inoculated 
intravenously with 1.8 X 10^^ syncytia fomning units of BIV R29 propagated in fetal 
bovine lung cells (FBL) (9). Five of the eight calves received 1 x 10^ peripheral 
blood mononuclear cells (PBMC) from a lymphocytotic cow persistently infected 
with BLV as part of a separate study on the interactive effects of the two viruses. 
The other three calves also received 10^ PBMC from a BLV-free calf. Three control 
calves were inoculated with BlV-free FBL and normal PBMC. Groups were housed 
in separate pens, and monitored daily for external signs of clinical disease. Blood 
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was collected by jugular venipuncture on a weekly basis for the first 11 weeks post-
Inoculation (p.i.). then every four to twelve weeks thereafter through 190 weeks p.i. 
Total leukocytes were counted and mononuclear cell subset percentages were 
determined by flow cytometry at similar internals as part of another study (K.P. 
Flaming, manuscript in preparation). 
Virus isolation 
PBMC were isolated from whole blood by centrifugation, collection of the 
buffy coat, and hypotonic lysis of erythrocytes (28). Approximately 10^ PBMC were 
co-cultivated with primary FBL (9) in the presence of eight i^g/ml polybrene. 
Cultures were passaged twice weekly and visually monitored for syncytium 
formation. At each passage, duplicate cultures were assayed for the presence of 
BIV, BLV, and bovine syncytium-forming virus using immunofluorescence or 
immunoperoxidase assays (9,35). Serologic reagents used for detection of BIV 
included convalescent serum from a calf experimentally infected with BIV (9), and 
BIV p26-specific monoclonal antibodies (35). For detection of BLV, high-titered 
antisera was collected from a sheep experimentally inoculated with PBMC from a 
BLV-infected cow with persistent lymphocytosis. In most cases, cells were sub-
cultured at least three times before they were considered virus negative. 
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BIV antigens and immunologic reagents 
The cloning and expression of BIV recombinant TrpE fusion proteins has 
been reported (2,11,35,38). The clone referred to here as BIV gag-3 contains the 
entire p26 coding region of BIV and small flanking regions on the 3' and 5' ends, 
ligated Into a pATH expression vector. The env-8 clone similarly expresses a 
fusion protein containing 134 amino acids from the amino terminal portion of the 
BIV transmembrane envelope protein gp42, which appears to contain a major 
immunoreactlve epitope of BIV (11). Following induction of protein expression, the 
bacteria were lysed, and recombinant proteins (Gag3 or Env8) were precipitated, 
washed, dissolved in 0.5% SDS, and stored at -70°C. 
To obtain hyperimmune antisera to BIV p26, rabbits were immunized 
intramusculariy with 100 ^.g Gag3 (1 mg/ml in 0.5% SDS) every two to three weeks 
for a total of five doses. The first dose was administered in an equal volume of a 
microparticulate stabilized water-in-oil squalene emulsion (Titer Max; Vaxcel, Inc., 
Norcross, GA); remaining doses consisted of Gag3 dissolved in 0.5% SDS. 
Beginning after the second injection, blood samples were screened for reactivity to 
Gag3 and BIV p26 by Western immunoblotting. BIV p26-specific monoclonal 
antibodies were generated against Gag3 as reported (35). Hybridoma 
supematants were screened on the basis of reactivity to p26 from purified BIV. 
MAb #104 recognized both the 65 kDa Gag3 protein and a smaller band of about 
54 kDa, which was not recognized by some other p26-specific MAbs (35). 
67 
Western immunobiotting 
Aliquots containing 30 jig of Gag3 only or 30 ng each of Gag3 and Env8 
were resolved by SDS-PAGE on 10% preparative gels at 200V for 35 minutes in a 
Bio-Rad (Richmond, CA) mini-Protean system. Proteins were transfen-ed to 
nitrocellulose membranes at 100V for 60 minutes using a Bio-Rad transblot system. 
Membranes were blocked ovemight at 4°C in 1% gelatin in TST (lOmM Tris, 150 
mM NaCI, 0.1% Tween 20). Washed membranes were placed in a Miniblotter 16 
or 28 apparatus (Immunetics, Cambridge, MA), incubated with 1:20 test sera at 
room temperature for 2 hours, washed again, and incubated for 1 hour with 0.06 
jiCi/ml of I^Sf-iabeled protein G (Amersham, Arilngton Heights, IL). Membranes 
were air-dried and placed on radiographic film for 12-48 hours at -70°C. 
Immunoprecipitation of GagS 
After patterns of antibody reactivity to BIV antigens were determined by 
immunobiotting, immunopreciprtations were performed to detect antibodies specific 
for conformational epitopes of non-reduced Gag3. To minimize non-specific 
binding, the Gag3 preparation was pre-cleared by ovemight incubation with protein 
G-agarose beads (Boehringer Mannheim, Indianapolis, IN). Twenty i^l test serum, 
alone or mixed with 0.5 ng pre-cleared GagS, was brought to 200 nl volume In lysis 
buffer (8) containing 1% Nonidet P-40, 0.5% deoxycholate, and 0.1% SDS, and 
Incubated 2 hours with rotation at room temperature. Ten fig protein G-agarose 
beads was then added to precipitate IgG Immune complexes. After 2 hours, beads 
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were pelleted by brief centrifugation, washed three times in 1 ml lysis buffer, and 
boiled to separate bound antigen from the complexes. Immunoprecipitated 
antigens were detected by immunoblotting using polyclonal rabbit anti-Gag3 
antibody diluted 1:500, followed by incubation with protein G as stated above. 
Results 
Virus recovery and clinical observations 
BIV was readily recovered from PBMC of all but one animal on four separate 
occasions during the first 24 weeks p.i. (Table 1). Only two cattle, #342 and 345, 
were BlV-positive at every isolation attempt during the period of study. Animal 
#348 was BlV-negative on only one occasion, and #341 and 347 tested negative 
twice. Animal #344, however, was unique in remaining consistently BlV-negative 
after week 17 of the study. There was no apparent difference in pattems of BIV 
recovery from PBMC of animals inoculated with BIV alone (#340, 341, 342) and 
those co-infected with BLV (#344, 345, 347, 348, 349). 
Previous studies have indicated that during the first six weeks p.i., mean 
lymphocyte counts were significantly higher in the BlV-inoculated animals 
compared to uninfected control calves (9). However, from ten weeks through four 
years p.i., there were no consistent BlV-induced changes in numbers of total 
leukocytes, GD4+ or CD8+ T cells, B cells, or monocytes (K. P. Flaming, manuscript 
in preparation). In addition, no lymphadenopathy or other clinical abnormalities 
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attributable to BIV were noted in any of these cattle through four years p.i. One BIV-
Infected animal developed fatal lymphosarcoma at six months p.i. and was not 
included in the present study.infected animal developed fatal lymphosarcoma at six 
months p.i. and was not included in the present study. 
Table 1. Recovery of virus from PBMC of cattle experimentally infected with BIV or 
with BIV and BLV 
Virus Recoveryc-weeks post-inoculation 
Animal Inoculumb 2 6 16 27 52 75 95 112 143 166 190 
340a BIV + + + + - - + + - - -
341 BIV + + + + - - + + + + + 
342 BIV + + + + + + + + + + + 
344 BIV + + 
BLV + + + + + + + + + + + 
345 BIV + + + + + + + + + + 
BLV + + + + + + + + + + + 
347 BIV + + + + + + + + + 
BLV + + + + - + - - + + -
348 BIV + + + + + + + + + + 
BLV + + + + + + + + + + + 
349 BIV + + + + _ + + + 
BLV + + + + + — — + + + 
®This animal is persistenth/ infected with bovine syncyta virus 
''Bght calves were inoculated intravenously with 1.8 X10  ^syncytia fomiing units of BIV R29 in fetal 
bovine lung cells; five also received 10  ^PBMC from a lymphocytotic cow persistently infected with 
BLV. 
i^rus was isolated by coculturing 10  ^PBMC with FBL cells and monitoring for syncytia formation; 
viruses were differentiated by immunocytochemistry. Cultures were passed at least three times 
before they were considered negative. 
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Patterns of antibody reactivity to BIV Gag3 recombinant protein by 
immunoblotting 
Sequential serum samples from cattle experimentally infected with BIV R29 
exhibited detectable IgG reactivity to recombinant GagS by four weeks p.i., as 
exemplified by animal #342 (Fig. 1), In seven of eight BlV-infected cattle, antibody 
reactivity to Gag3 began to decrease between six and ten weeks after infection, 
and diminished to low or undetectable levels by week 40. This loss of anti-Gag 
reactivity was not associated with any predictable changes in viral activity. For 
example, although Gag-specific antibodies were lost over a similar period of time in 
all seven cattle, virus was recoverable from the PBMC of animals #342 and #345 
throughout the study, while recovery from animals #340, #341, and #349 was less 
consistent (Table 1). In most instances, two to three blind passages were required 
to detect BIV replication by immunocytochemistry. Additional experiments 
demonstrated that there was not a linear relationship between the number of virus-
infected cells and the number of passages required for detection of virus replication 
(not shown). Therefore, it was not possible to quantitatively compare BlV-infected 
PBMC with the antibody titer to Gag and/or Env. Similarly, the antibody reactivity 
detectable by Westem blotting is not strictly quantitiative, but rather represents an 
overall decline in Gag-specific antibodies. 
A different pattern of antibody reactivity was seen with sera from calf #344. 
Anti-Gag reactivity in this animal remained easily detectable through at least 166 
weeks p.i. (Fig. 1 & 2). In addition, reactivity to the BlV-specific 54-kDa band 
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appeared to be more pronounced in this animal compared to others, indicating that 
different or additional p26-specific epitopes may have been recognized. 
Interestingly, this prolonged anti-Gag reactivity was observed only in the single 
animal which remained consistently negative for virus recovery beyond week 27. 
Weeks post-BIV inoculation 
0 2 4 6 10 16 27 40 60 75 95 + Mab 0 2 4 6 10 16 27 40 60 75 95 + Mab 
200-
97.4-
Calf#342 Calf #344 
Figure 1. Seroreactivity to the 65 kDa Gag3 recombinant fusion protein in cattle 
experimentally infected with BIV. All serum samples were diluted 1 ;20 in TST 
buffer for testing. Positive controls consisted of a 1:20 dilution of convalescent 
bovine serum collected 40 days post-BIV inoculation (+) (10), along with undiluted 
BIV p26-specific monoclonal antibody #104 (MAb) (35). Seven of the eight BIV-
infected animals exhibited reactivity patterns very similar to animal #342, but only 
animal #344 had persistent reactivity to GagS throughout the study. There was no 
comparable reactivity to lysates from bacteria transfomied with pATH alone (data 
not shown): thus, reactivity was specific for the BIV gag-encoded portion of the 
fusion protein. Bands of approximately 40 and 46 kDa presumably represent 
varying reactivity to non-BlV E. coli proteins that remain in the antigen preparations. 
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Antibody reactivity to Env8 
A BIV env-encoded recombinant fusion protein was used to further 
characterize the specificity of the antibody loss. Seroreactivity to Env8 was readily 
detectable throughout the study in all eight cattle, as shown for animals #341, 
#342, #344, and #349 (Fig. 2). Sera from all cattle continued to react to the Env8 
protein for over four years p.i. (data not shown). The persistence of reactivity to 
Env8 in Gag-seronegative cattle provides evidence for the Gag-specific nature of 
the early antibody loss. It should also be noted that the presence of BLV co-
infection appeared to have no consistent effect on the humoral response to BIV gag 
or env^-encoded proteins. 
Immunoprecipitation of Gag3 
To mle out the possibility that antibody reactivity shifted from linear to 
confomnational Gag epitopes over time, immunoprecipitation experiments were 
conducted using non-reduced Gag3. As shown for a representative animal in Fig. 
3 ("+" lanes), antibodies from all BlV-infected cattle precipitated non-denatured 
Gag3 by ten weeks p.i., with reactivity becoming greatly diminished by 60 weeks 
p.i. in seven out of eight animals. Moreover, no p26 bands were detected in the 
lanes (where no Gag3 was added), even in serum samples which had lost anti-
Gag reactivity. If p26 antigenemia was present in sufficient amounts to block Gag3 
antibodies, a p26 band of similar density to the precipitated Gag3 would have been 
expected to appear as reactivity to Gag3 diminished. This provides evidence that 
Figure. 2. Persistence of antibody reactivity to a BiV env-encoded protein. Equivalent amounts of Gag3 and Env8 
recombinant antigens were pre-mixed and resolved by preparative SDS-PAGE, followed by Western immunoblotting. 
Serum dilutions and positive controls are the same as described for Figure 1. Shown are representative examples of 
animals infected with BIV only (#341 and #342) and with BIV and BLV (#344 and #349). 
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the formation of p26-containing circulating immune complexes (CIC) does not 
account for the loss of anti-Gag reactivity. However, if CIC were rapidly cleared 
from the circulation, the assay used here might not have been sensitive enough to 
detect low levels remaining in the serum. 
Weeks post-BiV inoculation 
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Figure. 3. Immunoprecipitation of IgG immune complexes from BlV-infected cattle. 
Test sera were diluted 1:10 in the presence ("+" lanes) or absence lanes) of 
Gag3, then incubated with protein G-agarose beads and assayed for complexed 
GagS or BIV p26 by Western immunoblotting. The"+" lanes, therefore, would show 
the presence of antibodies capable of immunoprecipitating the non-reduced fomn 
of GagS. Seven of the BlV-infected cattle had patterns of reactivity similar to that 
shown for animal #342; while only animal #344 had prolonged reactivity. No p26 
was detected In any of the lanes, including those samples that had lost reactivity 
to Gag3. Positive control lanes (left) contain^ 10 micrograms of pelleted BIV or 
five micrograms of Gag3. •'25|-iabeled Protein G did not react with heavy chains of 
denatured bovine IgG transferred directly onto nitrocellulose membranes (data not 
shown). 
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Discussion 
In this study, longitudinal patterns of antibody reactivity to recombinant BIV 
proteins were determined in eight experimentally infected cattle, all of which have 
remained clinically healthy for over four years p.i. By four weeks p.i., strong 
antibody reactivity to BIV gag- and env-encoded recombinant fusion proteins was 
detectable by immunoblotting in sera from all animals. However, reactivity to the 
BIV Gag3 recombinant protein became greatly decreased or undetectable by 40 
weeks p.i. in seven cattle. Immunoprecipitation experiments revealed a similariy 
diminished reactivity to Gag3 confomnational epitopes by 60 weeks p.i. In contrast, 
reactivity to the Env8 recombinant protein was readily detectable in all BlV-infected 
cattle throughout the four-year study period, suggesting that the observed 
phenomenon specifically affected Gag-specific antibodies. Virus was recovered 
from the PBMC of each animal several times before and after the loss of Gag-
specific antibodies, and there was no obvious temporal association between the 
period of antibody loss and changes in virus recovery. Previous studies of 
serological reactivity in infections with other Antiviruses such as HIV, FIV, and 
visna virus have found a relationship between the loss of antibodies to viral core 
proteins and the development of clinical disease (1,5,10,12,15,17,18,19,21,27,29). 
In contrast, BIV infection has not been associated with disease, and we observed 
no signs of deteriorating health or consistent changes in lymphocyte subset counts 
in any cattle which had lost antibody to BIV core proteins. While it is possible that 
BlV-induced disease may yet develop in these animals, it is more likely that the 
relatively early loss of BIV Gag-specific antibodies occurs independently of 
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progression to overt disease. This observation suggests that alternative 
mechanisms may be responsible for the loss of Gag-specific antibodies in BiV 
Infection in comparison to other lentiviral infections. 
In HIV infection, it is postulated that increasing virus replication and p24 
antigen production can cause immune complex fonnation with concomitant loss of 
detectable antibody reactivity to p24 (1,7,17,21). However, the loss of antibodies to 
HIV core proteins has also been observed in the absence of detectable 
antigenemia or clinical symptoms, leading some investigators to hypothesize that 
other mechanisms may also play a role in this phenomenon (6,13,24,26). Indeed, 
it has been reported that PBMC from HIV p24 antibody-negative patients 
synthesize less Gag-specific antibody than p24 seropositive individuals (30,33). In 
the case of BIV, several lines of evidence argue against an Immune complex-
dependent mechanism as sufficient explanation for the loss of Gag-specific 
antibodies in Infected cattle. First, an immunoprecipltation assay revealed no direct 
evidence of p26-contalning immune complexes in any of the seven Gag-
seronegative cattle. In addition, there was no increase in virus recovery from the 
PBMC of these animals over time, as might have been expected if increasing viral 
replication accompanied the loss of Gag seroreactivity. Finally, no signs of immune 
complex disease have been obsen/ed in the Gag-seronegative animals. While it is 
possible that circulating immune complexes could have been removed from the 
blood by the mononuclear phagocytic system soon after their formation, it is 
unlikely that these animals would have remained clinically unaffected by prolonged 
high levels of virus replication and immune complex formation. 
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In view of this evidence, it is likely that immune complex-independent 
mechanisms are involved in the decline of BIV Gag-specific antibodies. Genetic 
differences in immune responsiveness to BIV Gag may account for some animal to 
animal variability, but are unlikely to account for the antibody loss in seven of eight 
animals. The maintenance of strong anti-Env reactivity in all eight cattle, along with 
virus recovery data, suggests that the loss of Gag-specific antibodies is not simply 
attributable to a functional latency of BIV in vivo. In fact, virus was most difficult to 
recover from the single animal which maintained antibodies to Gag throughout the 
study. One interpretation of these findings is that the presence of antibodies 
directed against certain Gag-specific epitopes might exert a protective effect 
against viral replication. However, the loss of anti-Gag reactivity over time did not 
lead to an increase in virus recovery in the other seven animals, as might have 
been expected if the presence of Gag-specific antibodies was protective. 
Continuing work should focus on the further elucidation of the mechanism(s) 
behind the loss of Gag-specific antibodies, which would increase our 
understanding of host-virus interactions during periods of clinical quiescence in 
other lentiviral infections. 
Lastly, these findings raise concern regarding serodiagnosis of BIV in 
naturally infected animals. In this study, seven out of eight BlV-infected cattle 
consistently lost detectable reactivity to either linear or conformational BIV Gag 
epitopes within 1 year p.i. Using antigens prepared from BlV-infected cell culture, 
Suarez et al recently reported a similar decline in anti-p26 antibodies in two cattle 
infected with either BIV R29-1203 or the recently described field isolate FL491 (31). 
Assays that rely on detection of anti-Gag antibody might therefore lead to an 
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underestimation of BIV infection rates, and a misunderstanding of the potential role 
of BIV in bovine health problems. The more prolonged seroreactivity to the Env8 
recombinant protein suggests that it would be a useful antigen for incorporation 
into BIV diagnostic assays. Reliable detection of BIV infection might also be 
achieved by PGR amplification of BlV-specific DNA (20,23,31,32). The use of more 
sensitive assays for detection of BIV infections will allow better epidemiologic 
studies to determine whether a loss of Gag-specific antibody reactivity is a common 
phenomenon in natural BIV infections. 
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CHAPTER 4. EFFECTS OF LONG-TERM INFECTION WITH BOVINE 
IMMUNODEFICIENCY VIRUS AND/OR BOVINE LEUKEMIA VIRUS ON 
HUMORAL AND LYMPHOCYTE PROLIFERATIVE RESPONSES 
IN CATTLE 
A paper to be submitted to Veterinary Immunology and Immunopathology 
Jeffrey A. Isaacson, Kevan P. Flaming, and James A. Roth 
Abstract 
Immune responses were examined in cattle experimentally infected with 
bovine Immunodeficiency virus (BIV) and/or bovine leukemia virus (BLV) for over 
three years. Lymphocyte proliferative responses to Con A or allogeneic MHO were 
determined by ^H-thymidine incorporation assays, and antigen-specific humoral 
and lymphocyte proliferative responses were measured following vaccination with 
tetanus toxoid (IT) and bovine herpes vims-1 (BHV-1). Lymphocytes from BIV-
infected cattle had significantly (p < 0.05) reduced proliferative responses to Con A, 
but responses to allo-MHC and TT did not differ from those of uninfected controls. 
BIV infection also had little effect on TT-specific antibody responses in vivo. In 
contrast, BLV-infected cattle had significantly increased secondary antibody 
responses to vaccination with TT, as well as enhancement of antibody responses 
to BHV-1, Numbers of circulating mononuclear cells were also higher in BLV-
infected cattle, which was attributable to Increases In both T and B cell numbers. 
Unstimulated lymphocytes from BLV-infected cattle had significantly increased 
spontaneous uptake of ^H-thymidine in vitro. When differences in counts per 
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minute were analyzed, lymphocytes from BLV-infected cattle had slightly increased 
proliferative responses to Con A, but no consistent alterations in responsiveness to 
allo-MHC, TT, or BHV-1. The increased humoral responses to non-BLV antigens in 
BLV-infected cattle, without a concomitant increase in antigen-specific lymphocyte 
proliferation In vitro, suggests that BLV infection may cause a non-specific B cell 
activation. 
Abbreviations 
BHV-1, bovine herpes virus-1; BIV, bovine immunodeficiency virus; BLV, 
bovine leukemia virus; BSV, bovine syncytium-fomriing virus; Con A, concanavalin 
A; CPM, counts per minute; DCPM, difference in CPM; ELISA, enzyme-linked 
immunosorbent assay; HIV, human immunodeficiency virus; HTLV, human T cell 
leukemia virus; MAb, monoclonal antibody; MHC, major histocompatibility complex; 
PBMC, peripheral blood mononuclear cells; PBS, phosphate-buffered saline; p.i., 
post-inoculation, PL, persistent lymphocytosis; SI, stimulation index; SLP, 
spontaneous lymphocyte proliferation; TT, tetanus toxoid; WBC, white blood cells. 
Introduction 
Cattle in the United States are susceptible to persistent infection by at least 
three distinct retroviruses; bovine syncytial virus (BSV), bovine immunodeficiency 
virus (BIV), and bovine leukemia virus (BLV). Like the spumavinjses of other 
species, BSV has not been associated with any bovine health problems (Jacobs at 
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al., 1995). Although BIV is genetically and structurally similar to 
immunosuppressive lentiviruses such as the human immunodeficiency virus (HIV), 
there has been no unequivocal evidence of BlV-induced disease in cattle 
experimentally Infected with either the original R29 isolate of BIV (Van der Maaten 
et al., 1972, Carpenter et al., 1992) or with recently described field isolates (Suarez 
et al., 1993). However, BIV infection has recently been associated with the 
development of an atypical T cell lymphosarcoma in an experimentally Infected calf 
(Rovid et al., 1996). BLV is an oncogenic retrovirus that can cause lymphoid 
tumors and persistent lymphocytosis in its host, although most infected cattle 
remain clinically and hematologically nomnal (Bumy et al., 1988). Therefore, these 
three retroviruses appear to cause asymptomatic infections in the majority of 
infected cattle. The asymptomatic stages of lentiviral and oncoviral infections in 
other species are often accompanied by altered immune functions. This suggests 
that BIV and/or BLV might similariy affect the immune responses of cattle in the 
absence of overt disease. 
Previous investigations have suggested that bovine immune functions may 
be compromised in the early stages of BIV infection. BlV-inoculated calves have 
been reported to have decreased monocyte functions and delayed humoral 
responses to protein antigens (Onuma et al., 1992), as well as decreased 
lymphocyte proliferative responses to mitogens (Martin et al., 1991) In the first year 
post-inoculation with BIV. However, these conclusions were based on a single 
sampling date, a single BlV-infected calf, and comparison to a single control 
animal, respectively, thus their significance is unclear. Studies of larger groups of 
BlV-infected cattle and controls over longer periods of time have found evidence of 
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depressed neutrophil functions (Flaming et al., 1993, Flaming et al., In press), but 
normal monocyte functions (Rovid et al., 1995) and relatively nonnal lymphocyte 
proliferative responses to mitogens (Flaming et al., in press) through four years p.i. 
Considering the ongoing concern about BIV as a factor in bovine health problems 
(Brownlie et al., 1994), as well as the potential importance of BIV as a model of HIV 
infection in humans (Gonda et al., 1990), further investigation of the effects of BIV 
infection on acquired immune responses in cattle is warranted. 
HIV provides a well-studied example of a lentiviral infection with differential 
effects on the host over time. Much evidence suggests that abnomialities in both T 
and B cell functions develop long before the loss of CD4+ T cells that coincides 
with the development of clinical symptoms. Lymphocytes isolated from the 
peripheral blood of most asymptomatic, HIV-infected individuals have been shown 
to lose responsiveness to various stimuli as the infection progresses: first to recall 
antigens, then to allogeneic MHC, and finally to mitogens (Shearer et al., 1986). 
Some clinically nonnal, HIV-infected humans also have decreased antibody 
responses following vaccination with tetanus toxoid or other antigens (Pinching, 
1991). SImilariy, feline immunodeficiency virus-infected, asymptomatic cats have 
been shown to have decreased proliferation of naive T cells to new antigens 
(Bishop et al., 1992) as well as to recall antigens (Torten et al., 1991) prior to any 
change in responses to mitogens or decline in CD4/CD8 ratios. If experimental BIV 
infection does adversely affect immune functions in outwardly healthy cattle, a 
reasonable hypothesis is that such manifestations might closely resemble those 
seen in the asymtomatic stages associated with other lentiviral infections. 
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Although considerably more research effort has been devoted to BLV than to 
BIV, the mechanism by which BLV can cause persistent lymphocytosis and/or 
lymphoid tumors in infected cattle remains unclear. BLV is closely related to the 
human T cell leukemia viruses, HTLV-I and -II (Sagata et al., 1995). There is 
evidence that humans with combined HIV and HTLV-II infection can have 
exacerbated immunosuppressive disease (Beiike et al., 1994). Therefore, it was of 
interest to detemnine whether co-infection with BIV and BLV would alter the effects 
of either virus on the bovine immune system. The present study was designed to 
investigate the effects of long-term infection with these viruses on humoral and cell-
mediated immune responses in cattle. 
Materials and Methods 
Animals and virus inoculations 
Colostrum-deprived newbom male Holstein calves were purchased from a 
local dairy and determined to be free of antibodies to BIV, BLV, and bovine viral 
diarrhea virus (BVDV). Since the BIV R29 isolate was known to be Infected with 
non-cytopathic BVDV, all calves were vaccinated with killed BVDV vaccine (EXCEL 
4; Bio-Ceutic, St. Joseph, MO) as previously described (Carpenter et al., 1992). At 
four to six months of age, animals were randomly divided into four groups: four 
calves were inoculated intravenously with 1.8 X 10^ syncytia fomning units of BIV 
R29 propagated in fetal bovine lung cells (FBL); five calves received 1 x 10^ 
peripheral blood mononuclear cells (PBMC) from a lymphocytotic cow persistently 
infected with BLV, but negative for BIV and BSV; and five calves received both BIV 
and BLV. The BlV-only calves also received 1 x 10^ PBMC from a BLV-free calf, 
and the BLV-only calves also received BlV-free FBL. Three control calves were 
sham-inoculated with normal PBMC and BlV-free FBL. A noncytopathic isolate of 
BVDV was included in the FBL inocula to control for the effects of BVDV in the BIV 
inocula (Roth et al., 1981). Groups were housed in separate pens and monitored 
daily for extemal signs of clinical disease. 
Peripheral blood cell counts 
Total and differential white blood cell (WBC) counts were monitored in BLV-
infected and uninfected cattle during the study period. Total WBC counts were 
determined on whole blood using an electronic particle counter, and differential 
counts were performed on Wright-stained whole blood smears. For analysis of 
phenotypic markers in freshly Isolated mononuclear cell subsets, PBMC were 
isolated as previously described (Flaming et al, 1993). Briefly, venous blood was 
collected into EDTA tubes, centrifuged, and buffy coats were diluted 1:1 in PBS and 
layered over Histopaque 1077 (Sigma). Following centrifugation at 400 x g for 30 
minutes, mononuclear cell layers were removed, washed, counted, and 
resuspended in PBS++ (PBS with 0.5% BSA and 0.1% sodium azide to stabalize 
membrane proteins) for monoclonal antibody (MAb) staining. Cells were labeled 
as described previously (Flaming et al., 1993) using MAbs obtained from VMRD, 
Inc. (Pullman, WA). T cell subsets were identified using antibodies reactive with 
CD2 (CH128A), CD4 (CACTI 38A), or CDS (CACT80C). In addition, a MAb to WC1 
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(BAQ4A) was used to identify the large proportion of circulating gamma-delta T 
cells that express this marker in cattle. A MAb against bovine IgM (Blg73A) was 
used to identify B cells, while monocytes were stained with GM1 (DH59B). A 
mouse MAb against irrelevant antigen served as an isotype control. 
After incubating 10® cells with 50 nl of primary antibodies (diluted 1:100), 
cells were washed and stained with 50 nl of a 1:100 dilution of fluorescein 
isoththiocyanate-conjugated goat anti-mouse Ig (heavy and light chain) from 
CalTag Laboratories Inc. (South San Francisco, CA). Washed cells were fixed in 
2% parafomnaldehyde in PBS. Fluorescence was determined at the Iowa State 
University Cell and Hybridoma Facility using a Coulter XL-MCL flow cytometer 
equipped with standard software. Between 5 x 10^ and 1 x 10^ cells were 
analyzed for each sample. Live cells were discriminated on the basis of their 
forward and side scatter parameters. 
Vaccinations 
At 34 months p.i., all cattle were immunized intramusculariy with a 
commercially available tetanus toxoid (TT) vaccine (Tetanus Toxoid, Fort Dodge 
Laboratories, Fort Dodge, lA). A second dose of TT vaccine was given to all cattle 
10 months later. The BLV-only and control cattle were later vaccinated twice with 
bovine herpes virus-1 (BHV-1). The first immunization contained attenuated live 
BHV-1 (Sanofi, Overiand Park, KS), and was given at 58 months p.i. In order to 
boost humoral responses, both groups were vaccinated two months later with a 
killed, gene-deleted BHV-1 vaccine (IBR/Marker, SyntroVet, Lenexa, KS). 
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Serology 
An ELISA to detect TT-specific antibodies in cattle was perfomned as 
previously described (Roth et al., 1984), with some modifications. Non-adjuvanted 
TT antigen for use in the ELISA was obtained from Fort Dodge Laboratories (Fort 
Dodge, lA). Immulon 4 plates (Costar, Cambridge, MA) were coated at 4°C 
overnight with 1.8 iig TT per well diluted in 100 |xl antigen binding buffer (0.02 M 
sodium carbonate/bicariDonate, pH 9.6). Plates were washed with phosphate 
buffered saline (PBS) in an automatic plate washer, and wells were blocked by 
adding 220 jil blocking solution (2% gelatin in PBS, pH 9.5-9.7) per well and 
incubating for 20 minutes at 39°C. Beginning with a 1:8 dilution for each sample, 
twofold serial dilutions were made across each row, for a final volume of 100 
p.l/well. Each plate contained a row of negative control wells, which contained 
similar dilutions of pooled sera from several cattle lacking detectable anti-TT titers. 
Serum samples known to contain high levels of anti-TT antibodies were also 
included as positive controls. Plates were covered and incubated at 39°C for 20 
minutes. After washing, 100 jxl of a 1:2000 dilution of peroxidase-conjugated anti-
bovine IgG heavy and light chain antibody (Kirkegaard and Perry, Gaithersburg, 
MD), was added to each well. Plates were incubated at 39° for 20 minutes, 
followed by washing and addition of 100 p.1 freshly mixed ABTS peroxidase 
substrate (Kirkegaard and Perry). Plates were incubated in the dark at 25°C for 10 
minutes, and 100 jil of 1 % SDS was added to stabilize color. Optical densities 
were immediately read at 405 nm. Means and standard deviations were computed 
for each dilution of test samples and negative control wells for all plates tested that 
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day. Anti-TT titer was defined as the highest dilution of each serum sample that 
gave absorbance readings greater than 3 standard deviations above the mean of 
all negative wells for that dilution. 
The control and BLV-infected groups of cattle later received two BHV-1 
vaccinations. Semm samples were obtained at various inten/als and stored at 
-20°C prior to submission to the Iowa State University Veterinary Diagnostic 
Laboratory for determination of BHV-1 serum neutralizing antibody titers. Endpoint 
neutralization titers were defined as the highest serum dilution that resulted In 
100% inhibition of BHV-1 cytopathic effects in vitro (Jenney and Snyder, 1981). 
Isolation of PBMC 
To isolate PBMC for use in lymphocyte proliferation assays, approximately 
200 ml of peripheral blood was collected from each animal into acid citrate 
dextrose, centrifuged, and buffy coats were harvested as previously described 
(Roth et al., 1982). Contaminating red blood cells were lysed with two volumes of 
cold distilled water, followed by restoration of nonnal osmolality with triple-strength 
PBS. Cells were washed twice in sterile PBS and cell numbers determined with an 
electronic particle counter. This procedure consistently yielded greater than 90% 
mononuclear cells as determined by Wright-Giemsa staining, and were 90-95% 
viable by Trypan blue exclusion staining. 
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Lymphocyte proliferation assays 
Prior to placing In cell culture, PBMC were diluted to 1 x 10® cells/ml In RPMI 
1640 (GIBCO Laboratories, Chagrin Falls, OH) with 10% fetal calf serum, 100 U 
ml-i penicillin, and 100 |i.g mh"" streptomycin. Cells were then added to 96 well flat-
bottomed tissue culture plates at a density of 2 x 10^ cells/well. Triplicate wells 
were either left untreated or were stimulated with final concentrations of 7.5 ng/ml 
concanavalin A (Con A) (Sigma), 0.5 |j.g/ml non-ad]uvanted TT, or 25 |xl/ml (1.25 
p.g/ml) of heat-Inactivated BHV-1. Cells were Incubated at SQ'C with 5% CO2 for 
either two (Con A) or four (TT or BHV-1) days, then labeled with 0.075 i^Ci/well ^H-
thymldine for 16-18 hours. Cells were harvested onto glass filter mats with a PHD 
Cell Harvester (Cambridge Technology, Inc., Watertown, MA), placed in vials with 5 
ml scintillation fluid, and ^H-thymidine uptake was determined with a MInaxI Tri-
Carb 400 Series scintillation counter (Packard Instruments, Downer's Grove, IL). 
Differences in counts per minute (DCPM) were calculated by subtracting average 
CPM in unstimulated wells from average CPM In treated wells for each animal, and 
stimulation indexes (SI) were calculated by dividing average treated CPM by 
average unstimulated CPM. 
Mixed leukocyte reactions 
Stimulator cells for one-way mixed leukocyte reactions consisted of PBMC 
Isolated from each of the three control animals, as well as from three other cattle 
that tested negative for antibodies to BSV, BIV, or BLV. Thus, lymphocyte 
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proliferative responses from each of the control animals were tested against PBMC 
from five animals, while all other cattle were tested for reactivity to six animals. 
Stimulator cells were inactivated by incubation of 1 x 10^ cells/ml with 50 jig/ml 
mitomycin C (Sigma) in the dark for 30 minutes at 39°C, followed by three washes 
in sterile PBS. Round-bottomed tissue culture plates were prepared with 2 x 10^ 
PBMC in 100 jxl/well from each animal to be tested. Either 2x105or2x104 
stimulator cells from each of the six non-infected animals were then added to 
triplicate wells for each test animal, for a total final volume of 200 ni/well. Additional 
wells received stimulator cells alone to insure that mitomycin C treatment 
prevented cell proliferation. Plates were incubated at 39°C in 5% CO2 for 6 days, 
then cells were labeled with 3H-thymidine and harvested as described above. 
Mean responses against stimulator cells from all (five or six) animals were 
analyzed. 
Statistical analysis 
For comparisons between ail four groups, data were analyzed as a 
completely randomized design with a 2 X 2 factorial an*angement of treatments. 
Main effects of BIV and BLV infection as well as viral interaction were examined. A 
main effect comparison tests the effect of an individual virus by comparing all 
animals that have been infected (for BIV it would be the BIV and BIV/BLV groups) 
versus all animals not infected with that particular virus (BLV and control groups). 
This type of design is more powerful and efficient than simply comparing singly 
infected animals (BIV) with the control group. A significant viral Interaction would 
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indicate that the effects of one (or both) viruses was not the same in animals that 
were infected with that virus alone versus animals that were infected with both 
viruses. Lymphocyte proliferation data for all four groups were analyzed using a 
repeated measures analysis. Titer data and TT-specific lymphocyte proliferation 
data were analyzed by day using an ANOVA to determine main effects and 
interaction of the factorial. All titer data were transformed (log 2) prior to analysis. 
In the studies involving vaccination with BHV-1, only control and BLV-only 
groups were included. These data were analyzed using a iog2 transformation of 
the raw titers and comparing group means by using the T test. Lymphocyte 
proliferation data were analyzed by day post-vaccination using the T test. 
Results 
Confirmation of viral infection 
As reported previously, BIV had been isolated from the PBMC of all BIV-
infected calves by two weeks p.i. (Carpenter et al., 1992, Isaacson et al., 1995), and 
BLV was isolated from the PBMC of all BLV-inoculated calves by eight weeks p.i. 
(Alexandersen et al., 1993, Isaacson et al., 1995). One animal in the BlV-only 
group also tested positive for BSV, but remained in the study. In addition, all BIV-
inoculated cattle seroconverted to BIV core antigens by four weeks p.i., and all had 
persistent antibody reactivity to a recombinant fusion protein containing the amino 
terminal portion of the BIV transmembrane envelope protein gp42 throughout the 
present study (Isaacson et al., 1995). All BLV-inoculated animals tested positive for 
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antibodies to BLV gp51 by an agar gel immunodiffusion test prior to beginning the 
present study (data not shown). 
Clinical monitoring 
No overt signs of illness were obsen^ed in any of the cattle during the study 
period. However, one animal in the BlV-only group (#346) died of an atypical non-
BLV lymphosarcoma at seven months p.i. (Rovid et al., 1996), and therefore was 
not a part of the present study. 
Peripheral blood counts 
Analysis of total and differential WBC and lymphocyte subsets in these cattle 
through the fourth year post-inoculation (p.i.) have been reported in a separate 
publication (Flaming et al, in press), and data from that study are repeated here 
only where relevant to the present study. Cattle infected with BIV had no long-term, 
consistent changes in either total or differential WBC counts, or in percentages of 
lymphocytes staining for B or T cell markers through 49 months p.i. (Flaming et al., 
in press), or in the present study (Table 1). In contrast, BLV-infected cattle had 
increased numbers of total WBC, mononuclear cells, and cells expressing CD2, 
CD4, WC1, or IgM in the fifth year p.i. (Table 1). Similar increases in these 
lymphocyte subsets have been previously reported in these BLV-infected cattle, 
although the alterations were not always statistically significant in each of the first 
four years p.i. (Flaming et al., in press). Neither BIV nor BLV infection had any 
Table 1. Comparison^ of cell numbers^ in peripheral blood for the fifth year p.i. 
Group WBC Granulocytes^ Mononuclears^ CD2+ CD4+ CD8+ WC1+ lgM+ CD4:CD8 CD2:lgM 
Control 5730 2530 3210 1580 950 490 280 540 1.95 2.99 
(±S.E.) ±603 ±70 ±530 ±350 ±190 ± 120 ± 120 ±340 ± 1 1  ±1.41 
BIV 5267 2140 3130 1530 860 550 280 730 1.57 2.13 
(±S.E.) ±473 ±569 ±980 ±390 ± 170 ± 140 ±90 ±230 ± 09 ±2 
BIV/BLV 7880L"' 2190 5690L"* 2150L* 1410L"* 730 780'-** 1510L*' 2.22 1.40 
(±S.E.) ± 1708 ±437 ± 1590 ±520 ±330 ±370 ±443 ±664 ±•78 ±.52 
BLV 6620L''' 2157 4460L*" 1900L' 1590L*** 730 720L- 890L" 2.23 2.10 
(±S.E.) ±545 ±617 ±720 ±516 ±445 ±241 ±341 ±329 ± .38 ±.75 
a L = BLV effect, I = BIV effect. X = interaction; * = p < 0.1, " = p < 0,05, "' = p < 0.01) 
cells per /7l of blood 
^ neutrophils, eosinophils, and basophils 
^ monocytes and lymphocytes 
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significant effect on CD4+: CD8+ orT cell: B cell ratios, (Table 1) Of the ten BLV-
infected cattle, only one animal (in the BIV/BLV group) had high enough 
lymphocyte counts to be considered persistently lymphocytotic through the first four 
years p.i. (Flaming et al., in press). In the fifth year p.i., the lymphocyte counts of 
this animal were still slightly above the upper prediction limits developed by 
Thumnond et al. (1990), while two others (one BIV/BLV, one BLV only) were 
considered borderline (data not shown). 
Humoral responses to tetanus toxoid 
Antibodies specific for TT were quantitated by ELISA before and after TT 
vaccinations. Tetanus antibody titers were either undetectable or less than 1:8 in 
all animals prior to vaccination. Following primary vaccination, anti-TT titers were 
significantly lower in the BlV-infected group at day 33, and remained lower, though 
not significantly so, through day 95 (Fig. 1(a)). After the second TT vaccination, the 
BIV/BLV and BLV groups had approximately fourfold higher humoral responses to 
the recall antigen, beginning at about 2 weeks post-vaccination (Fig. 1(b)). 
Therefore, coinfection with BIV appeared to have no effect on this enhancement of 
humoral responsiveness by BLV. The BLV effect was significant at the p < 0.1 level 
for seven of eight samplings taken between 22-135 days following the second 
vaccination (p < 0.01 for 5 samplings). 
99 
<D 
C 
CO (D 
(D 
E 
o 
CD 
o 
2000 
1 5 0 0 -
1000-
5 0 0  
1 0  2 0  3 0  4 0  5 0  6 0  
Days Post-1 st TT Vaccination 
70 
B. 
(U 
cz 
< 
c to a> 
o 
"S 
E 
o O) O 
35000 -
30000 -
25000• 
20000 -
15000-
10000-
5000-
2 0  4 0  6 0  8 0  1 0 0  1 2 0  1 4 0  
Days post-2nd TT vaccination 
—A— Control 
BIV 
BIV/BLV 
•— BLV 
A— Control 
BIV 
•— BIV/BLV 
BLV 
Figure 1. Effect of experimental BIV and/or BLV infection on humoral responses to 
tetanus toxoid (TT). Anti-TT titers were determined by ELISA. Geometric mean 
titers were calculated for statistical analysis, and these means were converted back 
to titers for plotting group means. Statistical differences are indicated as follows: I = 
BIV effect; L = BLV effect; X = interaction between the two vimses (* = p < 0.1; ** = 
p< 0.05; *** = p< 0.01). A. Primary responses. B. Secondary responses. 
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Lymphocyte proliferation 
Lymphocyte proliferative responses were determined by 3H-thymldine 
uptake in PBMC cultured either without additional stimulation (spontaneous 
lymphocyte proliferation or SLP), or following exposure to Con A, antigens, or 
allogeneic MHC. Group means for both stimulation indexes (SI) and differences in 
counts per minute (DCPM) were calculated and analyzed, but only DCPM results 
are depicted in Figure 2. Levels of SLP were significantly higher in the BLV-
infected cattle (Fig. 2(a)). Although there was considerable variation in SLP within 
the BLV groups (ranges were typically 100-1000 CPM for controls, 100-20,000 
CPM for BLV-infected cattle), SLP values remained relatively consistent for each 
individual animal during the study (data not shown). 
As shown in Rgure 2(a), BIV Infection was associated with a significant (p < 
0.05) decrease in levels of ^H-thymidine incorporation by lymphocytes stimulated 
with the T cell mitogen Con A in the fifth year p.i.. A previous study of these cattle 
had shown that lymphocyte proliferation in response to Con A during the fourth 
year p.i. tended to be decreased in BlV-infected cattle, but not in cattle infected with 
both BIV and BLV (Flaming et al., in press). A similar effect was seen in the present 
study, although the interaction between the two viral infections was not statistically 
significant. In addition, lymphocytes from BLV-infected animals had slightly 
enhanced responses to Con A in the fifth year p.i. (Fig. 2(a)). A similar response to 
Con A was reported for these BLV-infected cattle in the third year p.i., but in the 
fourth year p.i., lymphocyte proliferation in response to Con A was slightly lower in 
the BLV-infected groups compared to uninfected controls (Flaming et al, in press). 
Figure 2. Effect of bovine retroviral infections on lymphocyte proliferation in 
vitro. A. Spontaneous lymphocyte proliferation (SLP) refers to the counts per 
minute (CPM) due to spontaneous uptake of 3H-thymidine by PBMC in wells 
receiving no exogenous stimulation. Lymphocyte responses to Con A and 
mixed leukocyte reactions (MLR) are reported as differences in counts per 
minute (DCPM). Since the SLP and Con A treatments were included in all 
experiments as controls, these data represent means from 6-8 experiments 
conducted between 44 and 64 months p.i. Data were analyzed by repeated 
measures analysis. MLR were performed twice for each stimulator; responder 
cell ratio. A ratio of 1 ;1 indicates equal numbers of stimulator and responder 
cells were added to each well; in the 1 ;10 experiments, only one stimulator cell 
was added for every 10 responder cells. B. TT-specific lymphocyte proliferation 
by PBMC stimulated with TT in vitro. Viral effects and P values are represented 
as described for Rg. 1. 
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Thus, lymphocyte responses to Con A generally were not dramatically affected 
when DCPM were analyzed. However, when SI were compared instead, Con A 
induced lymphocyte proliferation appeared to be significantly decreased in the 
BLV-infected groups due to the higher levels of SLP (data not shown). 
Exposure of PBMC to allogeneic MHC in the fonn of mitomycin-C-inactivated 
PBMC from six uninfected cattle resulted in enhancement of ^H-thymidine uptake 
compared to unstimulated cells, but no significant differences in DCPM between 
the groups (Fig. 2(a)). As with Con A, when SI were compared, BLV infection 
appeared to cause a significant decrease in responses to allogeneic MHC, (data 
not shown), but this was entirely attributable to the increased background counts in 
PBMC from BLV-infected cattle. 
Because of the observation that bovine retroviral infections can affect 
humoral responses to tetanus toxoid vaccination in vivo, lymphocyte proliferation 
was also assessed in cultured PBMC stimulated with non-adjuvanted TT antigen. 
As shown in Figure 2(b), BIV or BLV Infection status had no consistent effect on the 
uptake of ^H-thymidine by PBMC exposed to TT in vitro. There was considerable 
variation in responses between different sampling dates, as well as between 
different animals within each group. Lymphocyte proliferation in response to TT 
appeared to be Increased in the BLV-only group 63 days post-vaccination, but this 
was predominantly due to exceptionally high values for one animal on that 
sampling date, and thus the means were not significantly different at the p < 0.05 
level. 
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Effect of BLV infection on immune responses to BHV-1 
In order to assess whether the BLV-induced enhancement of humoral 
responses was unique to tetanus toxoid, the five cattle infected with BLV and three 
uninfected controls were vaccinated twice with BHV1. As shown in Rg. 3(a), the 
BLV infected cattle had increased antibody responses to BHV-1, especially after 
the second vaccine was administered. However, geometric mean titers were 
significantly different between the groups at the p < 0.05 level for only two sampling 
dates. 
As shown in Fig. 3(b), vaccination with attenuated BHV1 increased the 
uptake of ^H-thymidine by lymphocytes from cattle treated with BHV1 in vitro. 
However, there were no consistent differences in BHV1-stimulated lymphocyte 
proliferation in PBMC cultures from BLV-infected and control cattle. 
Discussion 
In this study various immune parameters were examined in cattle between 
three and five years after experimental inoculation with BIV and/or BLV. 
Considering observations from other lentiviral infections, we hypothesized that a 
decline In antigen-specific immune responses might occur relatively early in the 
course of BIV infection, prior to any potential changes in circulating lymphocyte 
numbers or development of clinical signs. However, BIV infection caused no 
consistent alterations in humoral responses to vaccination with tetanus toxoid (TT), 
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Figure 3. Effect of BLV infection on humoral and lymphocyte proliferative 
responses to BHV-1 vaccination. A. Serum neutralizing responses to BHV-1 
vaccinations In control and BLV-only groups. Cattle were immunized first with 
modifed live BHV-1 (Vacc. #1), then with a killed BHV-1 product (Vacc. #2). B. 
Lymphocyte proliferation in PBMC stimulated with BHV-1 in vitro. Viral effects and 
P values are represented as described for Figure 1. 
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or in lymphocyte proliferative responses to TT or allogeneic MHC. Lymphocyte 
proliferative responses to Con A were decreased in BlV-infected cattle during the 
fifth year p.i. compared to uninfected controls. The mechanism of BlV-induced 
suppression of lymphocyte responsiveness to this T cell mitogen is unknown, but it 
may differ from that seen in HIV infection, where decreased lymphocyte responses 
to mitogens usually occur after the decline in responses to antigens and allogeneic 
MHC, and often coincides with the onset of clinical AIDS (Shearer et al., 1986). 
The results reported here suggest that experimental infection of cattle with 
BIV does not result in any obvious deficits in acquired immune responses 
duringthe first five years p.i. It is important to note, however, that similar to most 
previous studies of the effects of BIV infection, we examined cattle inoculated with 
the original R-29 strain of BIV, which may have been attenuated due to repeated 
passage in cell culture. Lower-passage BIV isolates are now available (Suarez et 
al, 1993), but there have been no reports thus far of the immune status of cattle 
infected for more than four months with these isolates. A recent study suggested 
that BIV may have played a role in the chronic health problems of a herd with a 
high rate of BIV infection (Snider et al., 1996). Because it is difficult to discern the 
role of BIV in natural infections due to the possible influence of other infectious 
agents or factors such as poor nutrition, toxins, and stress. It will be important to 
continue to investigate the effects of long-term experimental BIV infection on bovine 
immune functions under various experimental conditions. 
In order to examine the potential role of BLV as a co-factor in BIV infection, 
two groups of cattle in the present study were inoculated with BLV. Immune 
parameters of cattle infected with both BIV and BLV did not differ significantly from 
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those Infected with BLV only, indicating a lack of interaction between these viruses 
under these experimental conditions. In contrast, both groups of BLV-lnfected 
cattle had significantly Increased secondary antibody responses to TT vaccination 
compared to controls, and the BLV-lnfected group had consistently higher serum 
virus neutralizing antibody titers following vaccination with BHV-1. Cattle infected 
with BLV also had elevated numbers of circulating mononuclear cells, which was 
attributable to increases In both B and T cells, including WC1-expressing gamma-
delta T cells. Lymphocytes from BLV-infected cattle exhibited spontaneous 
lymphocyte proliferation and marginally increased proliferative responses to Con A 
(as determined by DCPM), but there was no consistent BLV effect on lymphocyte 
proliferative responses to TT, BHV-1, or allogeneic MHC. 
There have been few previous studies of the effect of BLV infection on 
Immune responses to non-BLV antigens. Cattle that develop BLV-induced 
lymphoma often exhibit signs of Immunosuppression In the terminal stages of 
disease (Jacobs et al., 1981, Yamamoto et al., 1984), but data on immune 
responses of clinically normal, BLV-infected cattle with or without persistent 
lymphocytosis are less clear. It has been known for many years that lymphocytes 
from some BLV-infected cattle undergo increased spontaneous proliferation in 
vitro. Decreased lymphocyte proliferative responses to mitogens, when calculated 
as stimulation Indexes, have sometimes been Interpreted as evidence for BLV-
induced immunosuppression (Muscoplat et al., 1974b, Takashima and Olson, 
1980), yet no such effect was observed when differences In CPM were analyzed 
Instead (Williams et al, 1988b). Similarly, because of the increased spontaneous 
proliferation of lymphocytes from BLV-infected cattle In the present study. 
108 
consideration of stimulation indexes only would have led to the conclusion that 
lymphocyte responses to Con A, allogeneic MHC, TT, and BHV-1 were significantly 
inhibited In the BLV-infected groups. However, our obsen^ation that BLV-infected 
cattle have increased secondary antibody responses to two different antigens, 
measured either as total antibody to TT or as BHV-1-neutralizing activity, suggests 
that BLV infection may enhance secondary antibody responses under a fairly 
broad range of immunization conditions. 
About 30% of BLV-infected cattle develop a persistent lymphocytosis that is 
often characterized by greatly increased numbers of circulating B cells (Muscoplat 
et al., 1974a, Takashima et al., 1977, Williams et al., 1988a, Gatei et al., 1989, 
Taylor et al., 1992). Several of these reports also described increased B cell 
numbers in BLV infected, non-lymphocytotic cattle. Although only one animal In 
the present study could be classified as persistently lymphocytotic, cattle in both 
BLV-infected groups had generally increased numbers of circulating B ceils. It 
seems reasonable to assume that an increase in numbers of antibody-producing 
cells would tend to enhance humoral responses to vaccination. What remains 
unclear, however, is whether the modest increase in B ceil numbers seen in these 
BLV-infected cattle completely accounts for the fairly dramatic increase in antibody 
responses reported here. 
There have been some conflicting reports on the effect of BLV infection on 
numbers of circulating T cells. In BLV-infected, lymphocytotic cattle, T cell numbers 
have been reported to be increased (Williams et al., 1988a, Stone et al., 1994), 
unaffected (Taylor et al., 1992), or decreased (Gatei et al., 1989, Sordillo et al., 
1994). Similariy, increased (Williams et al., 1988a), unchanged (Gatei et al, 1989), 
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and decreased (Sordillo et al., 1994) T cell numbers have been reported in BLV-
infected non-lymphocytotic cattle. The factors that determine T cell numbers in BLV 
infection are unknown, but it is likely that the increase In CD4+ T cell numbers seen 
in the present study contributed to the enhancement of antibody responses. These 
T cells would be expected to provide increased amounts of costimulatlon and/or 
soluble cytokines capable of enhancing B cell proliferation and differentiation. 
Moreover, increased numbers of B cells from BLV-infected lymphocytotic cattle 
were recently reported to express the Inducible alpha chain of the IL-2 receptor, 
suggesting that they might proliferate more In response to this cytokine (Stone et 
al., 1994). Increased amounts of IL-2 have also been detected In supematants of 
mitogen-stlmulated lymphocytes from BLV-infected, lymphocytotic cattle (Sordillo et 
al., 1994). Taken together with our In vivo results, these studies suggest that 
enhanced T cell-B cell interactions in BLV-infected cattle may result in increased 
antibody responses to T cell dependent antigens. 
Because of the potential relevance of BLV-induced Immune activation to the 
understanding of BLV pathogenesis. It will be important to determine whether 
enhancement of antibody responses occurs in cattle with BLV infections of varying 
durations, as well as In naturally acquired Infections. In addition, the knowledge 
that BLV infection may enhance antibody responses in cattle provides a strong 
rationale for screening cattle for BLV infection prior to Inclusion in vaccine trials or 
other immunological studies. BLV Infection has been associated with decreases In 
milk fat percentage and milk production (Wu et al., 1989, Da et al., 1993), as well as 
Increased culling rates (Brenner et al., 1989). An Interesting question to be 
answered Is whether stress due to chronic BLV-induced immune activation may 
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contribute to these BLV effects on production. Overall, much remains to be learned 
about the long-term effects of BLV and BIV infection on the host immune system. 
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CHAPTER 5. INCREASED MHC CLASS II AND CD25 EXPRESSION 
ON LYMPHOCYTES FROM NON-LYMPHOCYTOTIC CATTLE 
EXPERIMENTALLY INFECTED WITH BOVINE LEUKEMIA VIRUS 
A paper to be submitted to Veterinary Immunology and Immunopathology 
Jeffrey A. Isaacson, Kevan P. Flaming, and James A. Roth 
Abstract 
We recently observed that a group of cattle experimentally Infected with 
bovine leukemia virus (BLV) had enhanced antibody responses to recall antigens. 
None of the cattle in this group were classified as persistently lymphocytotic, but 
they did have significantly increased numbers of circulating T and B cells. 
Although the enhancement of humoral reactivity to non-BLV antigens might have 
been entirely due to the increase in lymphocyte numbers, we hypothesized that 
BLV-induced alterations in lymphocyte function could also have played a role. In 
order to investigate potential mechanisms of BLV-induced immune activation, dual-
color flow cytometry was used to compare the expression of MHC Class II (MHC II) 
molecules and the IL-2 receptor alpha chain (CD25) on lymphocyte subsets in 
freshly isolated and cultured PBMC from these same BLV-infected cattle (n=5) with 
that of age-matched controls (n=3). Freshly isolated peripheral blood mononuclear 
cells (PBMC) from BLV-infected cattle were found to contain a significantly 
increased percentage of B cells that expressed MHC II molecules compared to 
non-infected controls (P < 0.01). There were no differences between the groups in 
MHC II expression by T cells in unstimulated PBMC, but an Increased percentage 
of CD4+ T cells from BLV-infected cattle expressed MHC II after 20 hours of Con A 
stimulation (p < 0.05), and MHC II expression was increased on both CD4-t-
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(p < 0.01) and CD8+ (p < 0.05) T cells from BLV-infected cattle after 68 hours in 
vitro, even in the absence of exogenous mitogen. Although CD25 expression was 
not enhanced on freshly Isolated lymphocytes from BLV-lnfected cattle, an 
increased percentage of B cells from BLV-infected cattle expressed CD25 in 20 
hour cultures in the presence (p < 0.05) or absence (p < 0.01) of Con A. Thus, in 
addition to causing alterations In absolute numbers of circulating lymphocytes, BLV 
Infection can cause a functional activation of both B and T cells, even in cattle that 
are non-lymphocytotic. It is likely that these BLV-lnduced alterations in lymphocyte 
activation status contributed to the previously obsen/ed enhancement of antibody 
responses In vivo. 
Abbreviations 
BLV, bovine leukemia virus; Con A, concanavalin A; HTLV, human T cell 
leukemia virus; MHC II, major histocompatibility complex class II; PBMC, peripheral 
blood mononuclear cells; PBS, phosphate-buffered saline; PL, persistent 
lymphocytosis; sIgM, cell surface IgM. 
Introduction 
Bovine leukemia virus (BLV) is an exogenous retrovirus of cattle that 
predominantly infects B cells (Paul et al., 1977), although BLV provlral DNA has 
also been detected In T cells, monocytes, and granulocytes (Williams et al., 1988b, 
Schwartz et al., 1994). Approximately 30 percent of infected cattle eventually 
develop persistent lymphocytosis (PL), which Is characterized by dramatically 
increased numbers of circulating slgM+ B cells (Williams et al., 1988a, Gatel et al., 
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1989, Taylor et al., 1992). Although animals with PL are at a greater risk of 
developing BLV-induced lymphosarcoma, it remains unclear whether PL is a pre­
neoplastic state or a lymphoproliferative response to the presence of the virus. 
Because of the difficulty in detecting BLV proteins or BLV mRNA in freshly isolated 
lymphocytes or tissues, it has been proposed that BLV is functionally latent in vivo, 
especially in infected cattle that remain hematologically normal (Kettmann et a!., 
1980). More recently, the use of PCR-based techniques has allowed the detection 
of BLV-specific mRNA in PBMC from cattle at all stages of infection (Lagarias and 
Radke, 1989, Jensen et al., 1991), suggesting the latency of BLV infection is 
incomplete. One implication of these findings Is that persistent, low levels of BLV 
expression in vivo may influence host immune functions, even in BLV-infected, 
non-lymphocytotic cattle. 
There have been few studies of the effects of BLV infection on host immune 
system, particularly in cattle that remain apparently healthy. Although cattle In the 
terminal stages of BLV-induced lymphoma often have clear signs of 
immunosuppression (Trainin et al., 1976, Jacobs et al., 1981), there is little 
evidence to suggest that this is a general feature of BLV infection. In contrast, the 
findings of some recent studies imply that BLV infected cattle may cause an 
immune activation. The development of PL in BLV-infected cattle and sheep is 
also characterized by a dramatic expansion of the CD5+ B cell population 
(Lettesson et al., 1990, Matheise et al., 1992). Although the function of CDS on 
bovine B cells is unclear, an increased percentage (>15%) of CD5+ B cells from 
lymphocytotic cattle were shown to be activated cells with respect to increased 
DNA content and responsiveness to an IL-2-containing supematant (Maltheise et 
al., 1992). Stone et al. (1994) showed that an increased percentage of B cells from 
BLV-infected, lymphocytotic cattle expressed the inducible alpha chain of the IL-2 
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receptor (CD25) after stimulation with mitogens or recombinant IL-2 (Stone et al., 
1994, 1995). Supematemts from cultured PBMC of BLV-infected, lymphocytotic 
cattle were also found to contain Increased amounts of IL-2 (Sordillo et al., 1995). 
Therefore, BLV infection can potentially affect both B and T cell functions. It has 
been suggested that enhanced interactions between T and B cells may contribute 
to the activation and proliferation of B cells characteristic of PL (Stone et al., 1995). 
However, because most previous studies have focused on BLV-infected cattle with 
PL, an important question is whether BLV induces similar lymphocyte phenotypic 
alterations in the majority of BLV-infected cattle which do not develop PL. 
In an accompanying paper, we reported that BLV infected cattle had 
enhanced secondary antibody responses to two recall antigens, tetanus toxoid and 
bovine herpesvirus-1. Although none of the animals singly infected with BLV were 
considered to be lymphocytotic, BLV Infection induced significant increases 
(p < 0.05) in numbers of circulating T and B cells. Therefore, it was unclear 
whether the enhancement of antibody responses to non-BLV antigens was entirely 
attributable to the increased lymphocyte numbers, or whether functional changes in 
lymphocyte activity were also a contributing factor. In the current study, freshly 
isolated and cultured PBMC from the same BLV-infected cattle that had enhanced 
humoral responses to recall antigens were examined by dual-color flow cytometry 
for expression of Immune activation markers on specific lymphocyte subsets. The 
markers used were MHC Class II (MHC II) molecules and the IL-2 receptor alpha 
chain, CD25. There was evidence of increased activation of both B and T 
lymphocytes of BLV-infected, non-lymphocytotic cattle compared to uninfected 
controls. The results of these two studies indicate that a BLV-induced polyclonal 
lymphocyte activation may have played a role in the enhancement of antibody 
responses to non-BLV antigens. 
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Materials and Methods 
Animal inoculations 
Five colostrum-deprived, castrated male Holstein calves were Inoculated 
with BLV, and three calves were sham-inoculated as previously described 
(Carpenter et al., 1992, Isaacson et al, submitted). The cattle had been infected for 
four and one-half years at the beginning of the present study, which continued over 
a period of about one year. 
Peripheral blood cell counts 
Total and differential white blood cell counts were detemnined on whole 
blood, and lymphocyte subset percentages were quantitated in freshly isolated 
PBMC by flow cytometric analysis as previously described (Flaming et a!., 1993, 
Isaacson et al., submitted). 
Isolation of PBMC 
In order to provide sufficient numbers of PBMC for evaluating the effects of 
different culture conditions on the expression of cell surface mariners, 
approximately 200 ml venous blood from each animal was collected into acid 
citrate dextrose, followed by centrifugation, collection of buffy coats, and hypotonic 
lysis of contaminating erythrocytes (Roth et al, 1982). Cells were then washed 
119 
twice with sterile PBS and counted. Viability of PBMC prepared In this manner was 
consistently greater than 95% by Trypan blue dye exclusion. 
Culture and harvesting of cells 
For all in vitro studies, PBMC were diluted to 1 x 10® cells ml-"" in RPM11640 
(Celox Laboratories, Inc., Hopkins, MN) with 10% fetal calf serum, 100 U ml-i 
penicillin, and 100 ml""' streptomycin. For each animal, 2 x 10® cells (2 ml) 
were added to all wells of a 24-well flat-bottomed tissue culture plate, which 
allowed eight wells per treatment. One set of eight wells served as controls 
receiving no additional stimulation, while the other wells were treated with either 
Con A (7.5 |ig ml""*) or PWM (final dilution 1:100). Duplicate sets of plates were set 
up for each animal, and cells were incubated with 5% CO2 at 39°C for either 20 or 
68 hours prior to han/esting. Cells were removed from the wells by first centrifuging 
plates at 650 x g for 10 minutes, aspirating most of the supematants, then adding 
0.2 ml cold trypsin (Difco) In 0.5 mM EDTA at 4'C to loosen adherent cells. After 
incubating on ice for five minutes, 0.2 ml cold fetal calf serum was added to 
inactivate the trypsin. Cells were then removed from the wells by vigorous 
pipetting, and each well was rinsed once with 1 ml cold PBS to remove remaining 
cells. Staining of wells with crystal violet revealed that very few adherent cells 
remained in the wells after the washing step. Cells from a given treatment were 
pooled for each animal, and pooled cells were washed three times with cold 
PBS-H-, counted, and diluted to 10® viable cells mh"! in PBS++ (PBS with 0.5% 
BSA and 0.1% sodium azide) for incubation with antibodies. 
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Monoclonal antibodies (MAbs) 
Mouse MAbs reactive with the following bovine antigens were obtained from 
VMRD (Pullman, WA): CD4 (CACT83B); CDS (CACT80C); WC1 (BAQ4A); IgM 
(Blg73A), MHC Class II (TH14B), and the IL-2 receptor alpha chain or CD25 
(CACTI 08A). The MAbs against CD4, CDS, WC1, and IgM were all isotype lgG1; 
those reactive with MCHII and CD25 were lgG2a. Murine lgG1 and lgG2a MAbs of 
irrelevant specificities sen/ed as isotype controls. For secondary antibodies, 
affinity-Isolated FITC-conjugated anti-mouse IgGI (M32101) and PE-conjugated 
anti-mouse lgG2a (M32204) were purchased from Cal Tag Laboratories (San 
Francisco). Cross-reactivity experiments showed that freshly Isolated PBMC 
labeled with any of the IgGI primary MAbs showed less than five percent non­
specific reactivity with the lgG2a-specific reagent, and vice versa (data not shown). 
Cell staining and flow cytometry 
For MAb staining of both freshly Isolated and cultured PBMC, 1x10® cells 
were added to wells of 96 well microtiter plates. Duplicate wells received 25 p.1 of 
1:50 dilutions of primary MAb to either CD2, CD4, CDS, IgM, WC1, or GM1. Half of 
the wells for each treatment then received an additional 25 |il of anti-CD25, and 
half received anti-MHC II diluted 1:50 (final dilution 1:100 for each MAb), and plates 
were incubated for 25 to 40 minutes at 4*C. Cells were then washed 3 times in 
PBS++, and resuspended in 50 ^1 of a mixture of FITC-labeled anti-mouse IgGI 
and PE-labeled anti-mouse lgG2a (both diluted 1:100). Following another 25 to 40 
minutes incubation In the dark at 4* C, cells were washed in cold PBS and fixed in 
2% paraformaldehyde in PBS. 
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Fluorescence was determined at the Iowa State University Cell and 
Hybridoma Facility using a Coulter XL-MCL flow cytometer equipped with standard 
software. Between 5 x 10^ and 10 x 10^ cells were analyzed for each sample. 
Live cells were discriminated on the basis of their forward and side scatter 
parameters. Appropriate compensation was used to optimize dual color analysis. 
Statistical analyses 
All experiments were performed at least four times over a one year period. 
Treatment group means were compared using a repeated measures analysis of 
variance. Treatment effects were tested with animal(treatment) as the error tenn. 
Analyses were performed on lymphcyte subset percentages, the percentage of 
each cell type expressing MHC II or CD25, as well as absolute cell numbers 
(converted back to either total cells jil""' blood or total cells for each treatment in 
vitro). 
Results 
Confirmation of BLV infection 
As previously reported, BLV was isolated from the PBMC of all five BLV-
inoculated cattle by eight weeks p.i. (Alexandersen et al., 1993). All five BLV-
inoculated animals produced antibodies against BLV as detemriined by an agar gel 
immunodiffusion assay at the beginning of the study (data not shown). None of the 
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control animals tested positive for BLV antibodies prior to or during the study, nor 
did any of the eight cattle in the study test positive for antibodies to bovine 
immunodeficiency virus or bovine syncytial virus. 
Comparison of leukocyte populations in freshly isolated PBMC from 
BLV-infected vs. control animals 
As shown in Table 1, total circulating mononuclear cell counts tended to be 
higher in the BLV-infected group (p = 0.08). In earlier studies of these animals 
during the first five years p.i., BLV-infected groups had significant increases in 
numbers of mononuclear cells, B cells, and CD2+, CD4+, CD8+, and WC1+ T cells 
(Flaming et al., in press, Isaacson et al., submitted). However, with the exception of 
total mononuclear cell counts, these changes were not consistently present in each 
of the first five years p.i. The most likely explanation for the lack of statistically 
significant differences in mononuclear cell numbers in the present study is that only 
one group of five BLV-infected cattle was examined, therefore the statistical 
analysis was less powerful. However, a general trend towards increased numbers 
of both T and B cells continued to be observed. None of the cattle in the BLV-
infected group had lymphocyte counts high enough to be classified as persistently 
lymphocytotic during the study period (Thurmond et al., 1990), although one animal 
was considered borderiine. There were no significant differences between the 
groups in either CD4: CDS or T cell: B cell ratios (Table 1). 
Table 1. Effectsaof BLV Infection on numbers^ of white blood cells and lymphocyte subsets in peripheral blood 
Group WBC Granulocytes^ Mononuclears^ CD2+ CD4+ CD8+ WC1+ lgM+ CD4:CD8 CD2:lgM 
Control 5920 2810 3100 1770 1120 388 550 589 2.82 3.50 
BLV 8240 3220 5020* 2620 1860 675 501 763 2.84 3.54 
a * = p < 0 . 1 . ' •  =  p < 0 . 0 5 ,  " •  =  p < o . o i  
^ cells per p\ of blood 
^ neutrophils, eosinophils, and basophils 
^ monocytes and lymphocytes 
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Expression of activation markers CD25 and MHC II on lymphocyte 
subsets in freshly isolated PBMC 
Lymphocytes expressing surface CD4, CDS, WC1, or IgM in freshly isolated 
PBMC from BLV-infected and control cattle were analyzed for expression of 
immune activation markers MHC II and CD25. As shown In Figure 1 (a), there was 
a significant increase in the percentage of B cells expressing MHC II in PBMC from 
BLV-infected cattle (Fig. 1 (a)). Since BLV-infected cattle had increased numbers of 
circulating B cells, absolute numbers of MHC ll-expressing B cells were also 
significantly (p < 0.05) increased compared to controls (data not shown). There 
were no significant differences between the groups in the percentage of T cells 
expressing MHC II in freshly isolated PBMC (Fig. 1(a)), nor were there any 
differences between the groups in CD25 expression by any T cell subset (Fig. 
1 (b)). A decreased percentage of B cells from BLV-infected animals expressed the 
CD25 marker. However, because BLV-infected cattle had increased B cell 
numbers, absolute number of circulating B cells expressing CD25 did not differ 
significantly between the groups (data not shown). Therefore, circulating B cells 
from the BLV-infected cattle appeared to be activated with respect to MHC II, but 
not to CD25. 
Expression of MHC II by lymphocytes in cultured PBMC 
PBMC from BLV-infected and control cattle were cultured In the presence or 
absence of mitogens for either 20 or 68 hours, after which the expression of 
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Figure 1. Expression of MHC II and CD25 on lymphocyte subsets in freshly 
isolated PBMC from BLV-infected cattle (n = 5) and control cattle (n = 3). Data 
represent means of at least 3 separate sampling dates, analyzed by repeated 
measures analysis. P values for differences between BLV-infected and control 
groups are mai1<ed as follows: * = p < 0.1; ** = p < 0.05; *** = p < 0.01. A. 
Percentages of lymphocyte subsets expressing MHC II. B. Percentages of 
lymphocyte subsets expressing CD25. 
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activation maricers on lymphocyte subsets was detemfiined. Because there were 
no significant differences between the groups in total cell numbers under the 
various in vitro conditions (data not shown), analysis of cell numbers generally 
gave results that were consistent with the percentage data. As shown in Figure 
2(a), in PBMC cultured for 20 hours without exogenous mitogenic stimulation, the 
percentage of B cells expressing MHC II molecules was increased in the BLV 
infected group compared to controls, similar to the results for freshly isolated cells. 
Treatment of PBMC with Con A for 20 hours resulted in MHC II expression by 
nearly100% of B cells from the BLV-infected group, which was slightly, but 
significantly, higher than that of B cells from control animals. Con A stimulation 
also resulted in an increased percentage of CD4+ T cells from BLV-infected cattle 
expressing MHC II (p < 0.05), as well as a tendency for increased MHC II 
expression by CD8+ and WC1+ cells (Fig. 2(a)). In contrast, 20 hour treatment with 
PWM did not increase the percentage of T cells expressing MHC II in the BLV 
group compared to unstimulated cells. After 68 hours in culture. Increased 
percentages of CD4+, CD8+, and lgM+ lymphocytes from BLV-infected cattle 
expressed MHC II molecules, irrespective of the presence of mitogens. 
Expression of CD25 by lymphocytes in cultured PBMC 
Figure 3 shows the effect of culturing PBMC on the expression of the 
Inducible alpha chain of the lL-2 receptor, CD25. There was an increased 
percentage of B cells expressing CD25 in PBMC from BLV-infected cattle cultured 
for 20 hours, either with no additional stimulation or in the presence of Con A. 
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Figure 2. Effect of BLV infection on MHC II expression by cultured 
lymphocytes. Data are expressed as percentages of cells in each lymphocyte 
subset that also expressed MHC II. Data represent means of at least four separate 
sampling dates, analyzed by repeated measures analysis. PBMC were cultured for 
either 20 hours (A.) or 68 hours (8). P values for differences between BLV-infected 
and control groups are marked as follows: * = p<0.1;** = p< 0.05; "* = p < 0.01. 
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However, there were no differences in CD25 expression by any subset of 
lymphocytes in PBMC cultures treated with PWM. Interestingly, treatment with 
PWM actually appeared to depress the number of WC1+ T cells of both groups that 
expressed CD25 in 20 hour cultures compared to unstimulated cell, although no 
such effect was seen after 68 hours. 
Discussion 
The findings reported here add to an accumulating body of data indicating 
that BLV infection can have immunomodulatory effects in cattle. It had been 
previously shown that an increased percentage of B cells from BLV-lnfected cattle 
with PL express the alpha chain of the IL-2 receptor (CD25) following stimulation 
with mitogens or recombinant IL-2, and an increased percentage of circulating B 
cells from these cattle spontaneously expressed MHC II (Stone et al. 1994,1995). 
From these observations, it was suggested that a BLV-induced upregulation of 
molecules Important in both contact-dependent and cytokine-mediated interactions 
between B cells and T cells could contribute to the B cell proliferation that is 
characteristic of PL. In the present study, however, a similar increase in the 
percentage of B cells expressing MHC II was found in freshly isolated PBMC from 
BLV-infected animals lacking PL, and an increased percentage of B cells from 
these BLV-infected, non-PL animals expressed CD25 after culturing for 20 hours, 
either in the presence or absence of Con A. Therefore, while an upregulated 
expression of surface molecules Important in B cell-T cell interactions may be 
necessary for the manifestation of PL, it does not appear to be sufficient. Other 
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lymphocytes. Data are presented as described for Figure 2. 
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factors may also be important In determining susceptibility or resistance to PL. 
Resistance to PL has been shown to be highly associated with certain MHC (BoLA) 
types in cattle (Lewin and Bemoco, 1986, Lewin et al., 1988). Although the 
molecular basis for this resistance is not known, the trait has recently been 
associated with the presence of the amino acids Glu-Arg at the putative antigen 
binding region of the BoLA-DFRB3 MHC class II molecule, suggesting a potential 
role for cell-mediated immune responses in conferring resistance to PL (Lewin, 
1994). In addition, a non-immunoglobulin, non-interferon factor capable of 
blocking BLV transcription is present in the plasma and lymphatic fluid (Gupta et al 
182, Gupta and Ferrer 1984, Zandomeni et al., 1992); it is conceivable that lower 
levels of this factor are present in infected cattle that develop PL compared to those 
that remain hematologically normal. Thus, cattle that develop PL may be those that 
are unable to control the proliferation of BLV-infected cells. 
As described in an accompanying paper, we previously observed that these 
BLV-infected cattle had enhanced antibody responses to recall antigens compared 
to uninfected controls. It is likely that this was at least partly due to the overall 
increase in circulating B and T cell numbers in the BLV-infected group. However, 
the observation that BLV infection results in an increased percentage of B cells 
expressing MHC II molecules suggests a possible functional explanation for the 
enhancement of secondary antibody response of these animals. During the 
primary response to T cell-dependent antigens, several types of accessory cells 
have been shown to play a role in presenting antigenic peptides to CD4-t- helper T 
cells via MHC II molecules. However, B cells have been shown to be very efficient 
antigen presenting cells during secondary immune responses. The Ig antigen 
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receptor on the B cell surface can capture its specific antigen at very low 
concentrations, which is then endocytosed, processed, and presented on MHC II 
molecules to CD4+ T cells. Therefore, in BLV-infected animals, an increase in 
MHC ll-mediated antigen presentation by B cells would presumably result in 
increased stimulation of memory CD4+ cells during repeated antigen exposure, 
which would in turn provide more help for B cell antibody production. Such a 
mechanism could contribute to the enhancement of secondary antibody responses 
in BLV-infected animals. 
In addition to their important function in antigen presentation. MHC II 
molecules on the surface of B cells are capable of generating intracellular signals 
that lead to the proliferation of primed B cells (Cambier and Lehmann, 1989). 
Treatment of murine B cells with F(ab')2 fragments of anti-MHC II monoclonal 
antibody induced a rise in intracellular cyclic AMP (cAMP) and translocation of 
protein kinase C (PKC) to the nucleus (Lane et al., 1988). Interestingly, there is 
evidence that both cAMP and PKC are involved in regulating BLV transcription. 
The BLV LTR contains several sites that bind to cAMP-responsive elements 
(Willems et al., 1992), and activation of PKC in BLV-infected cells increases BLV 
transcription (Jensen et al., 1992). Therefore, the engagement of MHC II molecules 
could upregulate BLV transcription by increasing the activity of these intracellular 
signalling molecules. An intriguing possibility is that BLV may have developed a 
strategy to upregulate MHC II expression in order to enhance its own replication. In 
humans infected with the human T cell leukemia virus (HTLV), which is closely 
related to BLV, the HTLV Tax protein has been shown to interact with several host 
transcription factors, resulting in upregulated expression of both IL-2 and its 
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receptor (Greene et al., 1986), BLV Tax mRNA has been detected in freshly 
Isolated PBMC from animals with PL or tumors, and to a lesser extent In BLV+, non-
PL animals (Haas et al., 1992). In addition, Alexandersen et. al. (1993) reported 
that the expression level of two products of altemative BLV mRNA splicing, GIV and 
Rill, in BLV-infected cells was correlated with increased numbers of circulating 
lymphocytes. It Is unknown at present, however, whether any of these viral 
products directly Influence MHC II expression, or whether the observed increase in 
MHC 11 expression may simply result from chronic antigenic stimulation due to the 
production of BLV antigens. 
In addition to their presence on classical antigen presenting cells, MHO II 
molecules are also expressed on T cells in some species. Although the function of 
MHC II molecules on these cells Is unknown, there is evidence that they are 
capable of delivering costimulatory signals in human T cells (Odum et al, 1993, 
Spertini et al., 1992). MHC II expression was upregulated on T cells from BLV-
infected, PL cattle following stimulation with mitogens or recombinant IL-2 (Stone, 
et al., 1995). In the present study, an increased percentage of T cells from BLV-
infected, non-PL cattle expressed MHC II molecules after 20 hours in the presence 
of Con A, or after 68 hours in vitro in the absence of exogenous mitogens. Since 
BLV provlral DNA has been detected in T cells. It Is possible that the expression of 
MHC II molecules is a direct effect of BLV Infection, or it may occur subsequent to 
the activation of BLV-infected B cells In vitro. The increased expression of 
activation markers on cultured lymphocytes from BLV-infected cattle (CD25 by B 
cells, MHC 11 by T cells) in the absence of additional mitogenic stimulation is at 
variance with previous studies showing that mitogenic stimulation is necessary to 
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observe these effects. Compared to previous studies, the longer culture times used 
in the present study may have allowed the detection of increased T ceil MHC II 
expression in cultures receiving no mitogens, since the maximum culture time in a 
previous study was 48 hours (Stone et al, 1995). Altematively, the effects of BLV 
infection on the expression of activation markers may be qualitatively different in 
cattle with PL vs. non-PL. 
Many of the previous studies examining the effects of BLV infection on the 
host immune system have focused on animals with tumors or PL. In contrast, the 
experiments reported here and in an accompanying paper showed evidence of 
enhanced lymphocyte activation in BLV-infected, non-lymphocytotic cattle. As 
noted earlier, the majority of BLV-infected cattle remain clinically asymptomatic and 
do not develop PL, at least in the lifespan allotted to most cattle. Although 
enhancement of humoral immune responses might at first be considered as a 
potential advantage, it is also possible that an overall increase in B cell activation 
could reflect a detrimental alteration in normal host immunoregulation. Such a 
mechanism might contribute to the production losses and increased culling rates 
that have been associated with BLV infection (Brenner et al., 1989, Wu et al., 
1989). Regardless of the practical implications, a better understanding of 
mechanisms of immune enhancement in BLV-infected cattle will undoubtedly 
increase our overall understanding of BLV pathogenesis. 
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CHAPTER 6. SUMMARY AND GENERAL CONCLUSIONS 
Summary of Experimental Results 
In this dissertation, experiments have been described that address several 
aspects of the interactions between bovine immunodeficiency virus (BIV) and/or 
bovine leukemia virus (BLV) and the bovine immune system. In some lentiviral 
infections of other species, variations in the kinetics of antibody responses to 
specific viral proteins are associated with the development of disease. For 
example, in HIV-infected humans, a loss of antibody reactivity to p24, the major 
core protein, usually occurs concomitantly with the alterations in lymphocyte 
functions and decline in CD4 cell counts that acconnpany clinical AIDS (Biggar et 
al., 1985, Lange et al., 1986, Goudsmit et al., 1987, deWolf et al., 1988). Our 
hypothesis for the first study was that in cattle experimentally infected with BIV, 
monitoring of serum antibody to the major BIV core protein may serve as a 
predictor of the onset of decreased lymphocyte function and the onset of AIDS-like 
symptoms in cattle. Antibody responses to BIV proteins were studied in 
experimentally infected cattle (n = 8) by Western immunoblotting using two 
recombinant BIV fusion proteins; one (Gag3) containing p26, the major core protein 
of BIV, and another (Env8) containing the amino terminal portion of transmembrane 
BIV gp42. Although infected cattle developed antibodies reactive with both 
proteins, antibody reactivity to Gag3 declined to undetectable levels by about six 
months post-inoculation in seven out of eight cattle. However, none of these 
animals developed a decline in CD44- T cell counts or evidence of AIDS-like 
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symptoms for at least the next four years. Therefore, unlike human HIV infections, 
monitoring the levels of antibodies to the BIV major core protein was not a predictor 
of the onset of clinical disease. 
In contrast to the declining levels of antibody reactivity to Gag3, antibodies to 
the Env8 protein persisted in all cattle throughout the four year study period, 
suggesting that the loss of Gag-specific antibodies was not due to a complete 
abrogation of viral replication in vivo. Because of this observation, it was next 
hypothesized that the loss of Gag-specific antibodies was due to an increasing 
production of BIV p26 antigen in vivo, resulting in the fomnation of p26-containing 
immune complexes. However, the loss of BIV Gag-specific antibodies was not 
associated with smy obvious increase in the ease of virus recovery from PBMC. In 
addition, there were no clinical signs of developing immune complex disease in 
animals that had lost detectable Gag-specific antibodies. Immunoprecipitation 
experiments showed that although antibody reactivity to non-denatured GagS 
declined in a similar manner, there were no detectable levels of circulating p26-
containing immune complexes in cattle that had lost Gag-specific antibodies. 
Therefore, the loss of antibodies did not appear to be attributable to increasing viral 
replication with subsequent formation of p26-containing immune complexes. 
Interestingly, BIV could no longer be rescued from the PBMC of one animal (#344) 
by six weeks p.i., and this was the only animal that maintained detectable levels of 
Gag-specific antibodies throughout the study. However, since BIV was recovered 
from the PBMC most of the cattle while they were still Gag-seropositive, the 
presence of Gag-specific antibodies alone did not appear to prevent virus recovery. 
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Because there was no association between the loss of Gag-specific 
antibodies and clinically apparent signs of immunosuppression in BlV-infected 
cattle, the hypothesis for the second study was that a suppression of antigen-
specific immune responses played a role in the loss of antibodies in BIV infection. 
Previous studies of asymptomatic HIV-infected humans revealed a sequential loss 
of immune reactivity to recall antigens, then to allogeneic MHC, and finally to 
mitogens (Shearer et. a!., 1986). It was therefore expected that the earliest 
indicator(s) of BlV-induced immunosuppression would be a decreased 
responsiveness to a soluble protein antigen and/or to allogeneic MHC, rather than 
any loss of lymphocyte responses to mitogens, changes in circulating mononuclear 
cell numbers, or development of overt disease. These parameters wei-e examined 
in cattle infected for over three years with either BIV only (n = 3), BLV only (n = 5), 
both BIV and BLV (n = 5), as well as in sham-inoculated controls (n = 3). Because 
possible interactions had been described for the related human viruses HIV and 
HTLV, a second hypothesis that was tested in this study was that co-infection with 
BIV and BLV would alter the effects on immune responses induced by one or both 
viruses. As obsen/ed in earlier studies of these animals (Flaming et al., 1993, 
Flaming et al., in press), infection with BIV alone had no consistent effects on 
numbers of circulating CD4+ T cells, CD8+ T cells, WC1+ gamma-delta T cells, B 
cells, or monocytes. Lymphocytes from BlV-infected cattle did have significantly 
reduced proliferative responses to Con A during the fifth year p.i., which supports 
data obtained from these animals the first four years p.i. showing a tendency for 
cattle infected with BIV alone to have decreased lymphocyte responses to 
mitogens, although these earlier differences were not statistically significant 
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(Flaming et al., in press). BIV infection appeared to have little effect on allo-
reactivity or on antibody responses to vaccination with tetanus toxoid (TT). 
Therefore, for this group of cattle and at this stage of infection, the effects of BIV on 
host immune responses did not resemble those seen in early HIV disease, 
interestingly, cattle infected with either BLV only, or with BLV and BIV, had 
increased numbers of circulating B cells and T cells, slightly enhanced lymphocyte 
proliferative responses to Con A, and significantly enhanced secondary antibody 
responses to TT, as well as to a second antigen, bovine herpes virus-1. To our 
knowledge, this elevation of secondary antibody responses to specific antigens in 
BLV-infected animals has not been previously reported. 
Since the BLV-infected cattle in these experiments also had increased 
numbers of circulating lymphocytes, it was unclear whether the obsen/ed 
enhancement of antibody responses was entirely attributable to increased 
numbers of antigen-specific Immune cells. Our hypothesis was that in addition to 
these alterations in cell numbers, BLV infection also causes a lymphocyte 
activation which may have contributed to the enhancement of acquired immune 
responses. A third set of experiments was designed to test this hypothesis by 
comparing the expression of activation markers MHCII and CD25 on freshly 
isolated and cultured lymphocytes from BLV-infected cattle (n=5) with that of age-
matched controls (n=3). Freshly isolated PBMC from BLV-infected cattle were 
found to have a significantly increased percentage of B cells expressing MHCII 
molecules compared to non-infected controls. After 20 hours of Con A stimulation 
in vitro, B cells from BLV-infected animals also had enhanced expression of CD25 
(the inducible IL-2 receptor alpha chain) vs. controls Moreover, in PBMC cultured 
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with the T cell mitogen Con A for 20 hours, an increased percentage of T cells from 
BLV-infected cattle were also found to express MHCII molecules. An increased 
number of T cells from BLV-infected cattle also expressed MHCII molecules after 
68 hours in vitro in the absence of exogenous mitogens. It is therefore likely that 
BLV-lnduced alterations in lymphocyte function contributed to the enhancement of 
humoral responses in vivo. 
Practical Implications 
The loss of antibody reactivity to BIV Gag proteins in most BlV-infected cattle 
suggests that assays such as Western blotting, ELISA, or others that may rely on 
detection of Gag-specific antibodies will tend to underestimate the prevalence of 
BIV infection. Moreover, since BIV could still be isolated from the PBMC of cattle 
that had lost detectable Gag-specific antibodies, animals that are seronegative with 
respect to Gag reactivity would still be expected to be capable of transmitting BIV. 
Since antibody reactivity to the BIV Env8 recombinant protein persisted In all 
animals for at least four years post-inoculation, incorporation of this antigen into 
serological assays should allow a more accurate determination of BLV prevalence 
rates. 
Since cattle infected with BIV for over four years did not have any obvious 
defects in acquired immune responses, experimental BIV infection does not appear 
to cause the severe degree of immunosuppression seen in Infections with other 
lentlvimses such as HIV. However, since the incubation period of lentivlral 
diseases is often much longer than four years, any conclusions about these 
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findings must be qualified by the limited duration of infection. It is also important to 
note that these cattle were inoculated experimentally with the cell culture-adapted 
R29 strain of BIV, and lived in a relatively stress- and pathogen-free environment. 
Although the demonstration of relatively normal acquired immune responses in 
these animals Is a noteworthy contribution to the body of knowledge about BIV, it 
provides no information about the importance that such factors as route of 
inoculation, viral strain, environmental or physiological stress, or infectious 
cofactors (other than BLV) may play in the pathogenesis of BIV infection. 
Another important finding of this study was that there were no apparent 
interactions between BIV and BLV, Since cattle are often found to be infected with 
both viruses (Whetstone et al., 1990, Snider et al., 1996), any potentiation of the 
adverse effects of either virus infection would have been a cause for concem. Of 
course, the same caveats apply to these conclusions as to those in the previous 
paragraph. One possibility that we did not Investigate, however, was that 
coinfection with BIV and BLV might facilitate BIV transmission because of the BLV-
induced increase in numbers of circulating mononuclear cells. 
In the course of investigating the effects of coinfection with BIV and BLV, it 
was discovered that BLV-infected cattle had enhanced humoral responses, 
particulariy to recall antigens. The most obvious practical implication of this finding 
is that cattle used in immunological studies of any kind must be screened for BLV 
infection, since a BLV-induced enhancement of antibody responses would at best 
contribute to statistical variation, and at worst might lead to erroneous interpretation 
of experimental results. 
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Theoretical Considerations 
Because the loss of p24-spectfic antibodies In HIV infection is associated 
with disease development, the mechanistic basis for this relationship has been 
investigated. A simultaneous increase in the level of p24 antigenemia is often 
found in these patients, which had led to the hypothesis that p24-specific 
antibodies become undetectable because they are bound into circulating immune 
complexes due to an overwhelming production of antigen (McHugh et al., 1988, 
Nishanian et al., 1990). However, there is some evidence that the production of 
p24-specific antibodies is also reduced in some human AIDS patients (Barnes et 
al., 1988, Portera et al., 1990). In the present study, the loss of antibody reactivity to 
BIV occun-ed during the first six months post-inoculation. There was no evidence 
that the antibody loss was attributable to increased viremia, since circulating BIV 
p26-containing immune complexes were not detectable by immunoprecipitation, 
nor were there any increases in ability to isolate virus during or subsequent to the 
antibody loss. Moreover, there was no evidence of immune complex-induced 
disease in any of these cattle for at least 5 years p.i. Therefore, in contrast to HIV 
infection, an increasing production of Gag antigens and subsequent formation of 
Gag-containing circulating immune complexes did not appear to be an important 
explanation for the loss of Gag-specific antibodies in BlV-infected cattle. It is 
unknown at present, however, whether the antibody loss in BIV infected cattle is 
due to a decreased production of Gag-specific antibodies as has been reported in 
some HIV patients, or perhaps results from a unique mechanism, such as a 
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decreased production of BIV p26 in vivo or a selective loss of p26-specific antibody 
responses in the continuing presence of p26 antigen production. 
Despite the prodigious amount of research that has been devoted to BLV 
over the past 25 years, studies of the Immune responses of BLV-infected cattle to 
non-BLV antigens have been relatively scarce. Thus, it is perhaps not surprising 
that the two most important findings of the present studies of the immunological 
effects of BLV infection have not been previously reported: 1) that BLV-infected 
cattle can have enhanced humoral responses to recall antigens, and 2) this 
enhancement may be due in part to a BLV-induced lymphocyte activation, even in 
cattle that have not developed persistent lymphocytosis. 
The observation that humoral immune responses were enhanced in BLV+, 
non-PL cattle is a significant addition to an increasing body of evidence that BLV 
can cause immune activation in cattle that do not develop tumors. Most previous 
studies of the effect of BLV on immune functions have focused on cattle with tumors 
or PL. These studies have shown that an increased number of B cells from BLV+ 
PL cattle express surface molecules such as CD5, MHCII, and the IL-2 receptor 
alpha chain, all of which have been implicated as mariners of activated B cells 
(Possum et al., 1988, Lettesson et al., 1991, Maltheise et al., 1992, Sordillo et al., 
1994, Stone et al., 1994, 1995). Other investigators have reported an increased 
production of IL-2 in supematants of cultured PBMC from BLV+ PL cattle (Sordillo 
et al., 1994), as well as alterations in amounts of mRNA coding for various 
cytokines in both PL and non-PL cattle (Pyeon et al., 1996). Thus, the most 
important implication of the findings presented here is that the BLV-induced 
immune activation previously observed In vitro may also be manifested as 
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enhancement of humoral responses In vivo. In addition, the fact that enhancement 
of antibody responses was observed in non-PL cattle implies that it may be a 
general affect of BLV infection per se, rather than simply resulting from the dramatic 
increase in circulating B cell numbers seen in cattle with PL. 
Although the mechanism of BLV-induced enhancement of antibody 
responses in these animals is unknown, the increased expression of MHCII 
molecules by B cells in BLV-infected cattle may be a critically important factor. 
Although B cells are most often thought of as antibody-producing cells, they also 
serve an important role in processing and presenting antigens to CD4+ T cells, 
especially during secondary immune responses. The finding that increased 
numbers of B cells in BLV-infected cattle express MHCII implies that these B cell-
CD4+ T cell interactions would be facilitated in vivo. This would be expected to 
stimulate antigen-specific CD4+ T cells to proliferate and differentiate into cells 
capable of providing increased help to B cells in temris of soluble cytokines and cell 
surface costimulatory molecules. This would In tum result in increased 
differentiation and proliferation of antigen-specific B cells. Therefore, a BLV-
induced increase in B cell MHCII expression would be expected to contribute to the 
increases in lymphocyte numbers and functions that were reported in the present 
studies. More recent work has demonstrated that imbalances in the amounts of 
mRNA coding for cytokines such as IL-10, IL-2, and gamma interferon are present 
in PBMC of BLV-infected cattle with different manifestations of BLV infection (Pyeon 
et al., 1996). As more bovine cytokine-specific reagents become commercially 
available, it will be very interesting to detennine whether BLV infection causes host 
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T cells to secrete TH2-type cytokines, which would tend to enhance the 
proliferation and differentiation of B cells, which are the main targets of BLV. 
Both BIV and BLV are retrovimses that infect cells of the immune system, 
such as those found circulating In the peripheral blood. However, the overall 
findings of the research described in this dissertation suggest that while BIV 
appears to have a relatively mild Immunosuppressive effect during the early years 
post-Infection, BLV Infection tends to enhance both numbers and some activities of 
lymphocytes. Consideration of the different ways In which Antiviruses and 
oncoviruses utilize their host cell may provide some rationale for the different 
outcomes of BLV and BIV Infection. Both viruses produce a transactivating protein 
early In their life cycle that Is Important in regulating viral replication. Although 
cellular proteins have been shown to influence the replication of both viruses, the 
transactivating protein of BIV, Tat, can bind directly to the TAR region of BIV RNA 
independently of the presence of host transcription factors (Chen and Frankel, 
1995). Because the BLV Tax protein does not bind directly to the BLV LTR, the 
presence of cellular factors induced during cell activation is a much more stringent 
requirement for BLV replication. Therefore, BLV replication may be much more 
dependent on the activation of Its host cell, while BIV is able to complete Its life 
cycle with less need to manipulate Its host cell. This may have allowed BIV to 
evolve Into a relatively non-pathogenic, yet successful virus, while BLV has to work 
a little harder to succeed. 
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Recommendations for Future Research 
Mechanism(s) of BIV Gag-specific antibody loss 
In order to Increase our understanding of host-retrovlnjs Interactions, further 
research effort should be devoted to elucidating the cause of this unique pattern of 
antibody loss in BIV infection. Research should focus on other viral and/or host 
factors that could result in the loss of Gag-specific antibodies, such as whether the 
expression of BIV Gag proteins is downregulated in vivo at an early stage of viral 
infection. This could be investigated either by staining of lymphoid tissues for BIV 
p26 expression at various times post-inoculation, or by developing a quantitiative 
RT-PCR to amplify BIV Gag-specific RNA from the PBMC of infected animals. In 
addition. If a sensitive PCR-based assay can be developed for the detection of BIV 
virions, then the virus load of infected animals could be monitored over time as 
Gag-specific antibody levels decline . 
Another possible explanation for the loss of Gag-specific antibodies is that 
cells that are producing Gag proteins are selectively killed by a BIV Gag-specific 
cytotoxic T cell (CTL) response. This could provide a selective pressure favoring 
the sun/ival of BIV strains which express either a mutant Rev protein, or at least 
much lower levels of Rev which would reduce the amount of unspliced mRNA that 
is able to code for Gag proteins. The development of assays for the detection of 
CTL activity against specific BIV proteins would allow the detennination of whether 
the loss of Gag-specific antibodies correlates with such changes in CTL specficity. 
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A third possible hypothesis is that BIV infection specifically inhibits Gag-
specific antibody responses. In order to detemnine whether BIV Gag itself can 
suppress antibody responses in vitro, cultured PBMC from uninfected cattle could 
be treated with either BIV Gag3 recombinant protein or with overlapping peptides 
generated from the reported sequence of BIV p26. Effects of such treatment on 
lymphocyte proliferative responses to mitogens or antigens, or on expression of 
MHCII molecules by different mononuclear cell subsets could be determined by 
flow cytometry. It would be important to use irelevant peptides or recombinant 
proteins prepared In a similar manner as controls for nonspecfiic effects. In order to 
further investigate the possibilty that BIV inhibits Gag-specific responses by 
interfering with antigen presentation, antigen presenting cells (either monocytes or 
B cells) could be purfied by adherence or panning, treated with Gag3/peptides, 
then re-mixed with autologous cells and stimulated with antigen to determine the 
effects on monocyte-lymphocyte or lymphocyte-lymphocyte interactions. 
Effects of BIV on acquired immune responses 
The studies described here should be expanded to examine the effects of 
BIV infection on responses to other adjuvanted and non-adjuvanted antigens, as 
well as to T cell-independent antigens. In addition, delayed-type hypersensitivity 
reactions should be measured in BlV-infected cattle following sensitization with 
either Mycobacterium tuberculosis or M. bovis. In order to more thoroughly 
characterize the effects of BIV infection under more natural conditions, cattle should 
be infected with various strains of BIV, including recent Florida isolates (Suarez et 
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al., 1993). Animals should also be inoculated via non-intravenous routes, since 
natural infection probably can occur through intradermal or mucosal exposure. 
After varying incubation periods, infected and uninfected cattle should be exposed 
to environmental and physiological stresses to determine whether the presence of 
BIV might exacerbate the immunosuppression that is often seen in these situations. 
Immune responses should also be studied In cattle that have been naturally 
infected for varying periods, and compared to those of carefully matched controls. 
Mechanism(s) of BLV-induced enhancement of antibody responses 
The finding that BLV-infected cattle have enhanced antibody responses to 
recall antigens should be confirmed in naturally infected cattle, both with and 
without PL. Naturally infected cattle could be identified in a given herd using the 
AGIO test, and absolute lymphocyte counts determined for distinguishing cattle with 
PL. If possible, infected cattle would be separated from uninfected cattle to 
minimize transmission during the study, and controls would be re-tested at the end 
of the study to insure that none had seroconverted. Cattle would then be 
immunized with several different antigens, or different groups could be immunized 
with different antigens. Both T cell-dependent and T-independent antigens should 
be used, to better define the role of T cell help in the enhancement of antibody 
responses. Antibody and lymphocyte proliferative responses could then be 
compared as In the present study. 
A recent paper has shown that PBMC from BLV-infected cattle with PL 
contain higher levels of IL-10 mRNA compared to PBMC from BLV-infected, non-PL 
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cattle or uninfected cattle, while PBMC from the non-PL cattle contained the highest 
levels of IL-2 mRNA (Pyeon et al., 1996). It may be that BLV-infected cattle tend to 
develop a TH-2-type pattern of cytokine secretion, which could bias immune 
responses In favor of antibody production, to the detriment of cell-mediated 
responses. Consequently, It would be useful to measure either cytokine mRNA, or 
the production of various cytokines in cultured PBMC, at the same time as antibody 
responses are being characterized. In addition, delayed-type hypersensitivity 
responses could be assessed following sensitization of BLV-infected and control 
cattle to an antigen such as BCG, followed by skin testing. This would allow a 
determination of whether enhancement of antibody responses is associated with a 
particular pattem of cytokine production or loss of DTH responses. 
The potential role of specific BLV proteins, such as Tax, in the enhancement 
of antibody responses could be investigated in several ways. Cloning and 
expression of the BLV tax gene would allow the detemnination of whether treatment 
of uninfected lymphocyte cultures with soluble BLV Tax enhances SLP or 
expression of CDS, MHCII, IL-2, IL-2R or other molecules important in the control of 
lymphocyte activation. In addition, cells could be transfected with plasmid 
constructs where the BLV tax gene is under the expression of an inducible 
promoter; this would allow the effect of intracellular tax expression to be studied in 
various cell types. 
One other interesting possibility is that a BLV protein may act as a 
superantigen by fomiing a "superantigen bridge" between T cells that express a 
particular V beta chain and the MHCII molecules expressed on the surface of B 
cells or other antigen presenting cells. If a BLV protein was identified that causes 
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some proliferation of lymphocytes in vitro, the protein could be added to purified, 
Irradiated bovine T cells to allow binding to the TCR. These cells could then be 
washed and added to purified bovine B cells (in separate wells, addition of the BLV 
protein alone, as well as T cells that had been incubated with an irrelevant protein, 
would sen/e as controls) to determine whether interactions between the T cell-
bound BLV protein and B cell MHCII molecules would result in polyclonal B cell 
proliferation and Ig production. 
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